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CHAPTER 1 INTRODUCTION 
1.1 Antimicrobial resistance 
Microorganisms not only have a much longer history than human beings, they exist in 
greater quantities as well. Life on earth has a history of 3.7 billion years, 3 billion years of 
which microorganisms have been the single dominant form.1-2 They are found from the 
highest mountains to the deepest trenches; their biochemical reactions shaped the 
biosphere that we now live in today.3-4 If we were to summarize the earth’s history into one 
calendar year with the earth born on Jan 1st, the first two months would be barren, but from 
sometime in March, tiny microbes would start swimming in the warm coastal waters and 
around thermal vents. From March to October, two thirds of a year, microbes were the only 
life form; humans arrived on the last hour of the last day (Dec 31st) and have existed for no 
more than 30 minutes. The sheer quantity of microbes is almost beyond imagination. If we 
gather all the microbes on earth, not only would they outnumber all the humans, trees, pets, 
birds – all the visible world combined, they would outweigh them as well!5 As a late comer 
who falls short in number, it is no wonder that humans have developed mechanisms to 
coexist with microbes.  
Microbes do not just live with us, they also live on us. The exact number of microbes 
living on each person is still under debate. The most well-known ratio is 1:10,6-7 with 
microbes outnumbering human cells. A closer look suggests this famous ratio is perhaps 
only a back-of-the-envelope calculation8 with a more accurate estimate being that each 
human contains about 30 trillion human cells and 39 trillion microbial cells8 – nearly a tie. 
By any standard however, we are walking ecosystems and “we contain multitudes” as the 
science journalist Ed Yong puts it.9 We live in harmony with most of these microbes; some 
are even beneficial, they help us digest food, build immune systems, and may even 
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contribute to our mental health.10-11 Occasionally however, some microbe-human 
relationships go rogue, with devastating consequences. 
Before 1940, infections were a leading cause of death.12 The standard treatment for 
tuberculosis used to be fresh air; any chance of infection, even a paper cut could be fatal. 
The advent of antibiotics, considered by many to be one of the greatest achievements in 
modern medicine, has greatly reduced the mortality of bacterial infections in the United 
States and around the globe.13-14 Antibiotics, together with vaccination, sanitation and better 
hygiene practices to control infectious diseases15 contribute to an increase in successful 
child birth, a sharp drop in infant and child mortality16 and doubling of the average lifespan.17 
Unfortunately, resistance has accompanied antibiotics from nearly the first day of their 
use18-19 and the influences of resistance have grown constantly over time.20-21  
Contrary to popular belief, resistance is not a new phenomenon. The first reports of a 
pathogen developing resistance to penicillin appeared in 1944,22-24 a mere year after the 
drug began to be mass produced in 1943. Even Alexander Fleming, the discoverer of 
penicillin, warned of the development of resistance in his 1945 Nobel Prize acceptance 
speech.25 He described a hypothetical scenario where Patient X, who:  
buys some penicillin and gives himself, not enough to kill the streptococci but enough 
to educate them to resist penicillin. He then infects his wife. Mrs. X gets pneumonia and 
is treated with penicillin. As the streptococci are now resistant to penicillin the treatment 
fails. Mrs. X dies. 
Indeed, resistance has been found for every antibiotic ever discovered.26-27 
The origin of antibiotic resistance can be dated long before antibiotics being used by 
humans28-30 as studies have shown that antibiotic biosynthetic pathways and antibiotic 
resistant mechanisms began to co-evolve at least 30,000 years ago.31-32 Consistent with 
this notion is the finding that antibiotic resistance occurs in microbes isolated from extreme 
natural habitats including the deep ocean33 and deep terrestrial subsurface34, places 
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presumably that have little human influence.35-36 These reports suggest the unpleasant 
conclusion that resistance cannot be eradicated and thus humans must continue to develop 
new agents to treat otherwise intractable bacterial infections.37-40  
Historically, resistance was not a big concern because new antibiotics kept being 
launched into the market. From the discovery of the antimicrobial effects of sulfonamides in 
1932 by the German bacteriologist and pathologist Gerhard Domagk, penicillin and 
streptomycin were discovered in 1943, tetracycline in 1945, cephalosporin in 1948, 
erythromycin in 1949, and vancomycin in the 1950s. New classes of antibiotics were 
constantly emerging, not to mention upgrades of existing ones were also occurring.  
Since the end of the so-called “golden era” of antibacterial drug discovery in the 1970s, 
however, only two new classes of antibiotics have been launched to the market, linezolid41-
42 and daptomycin.43-45 Not unexpectedly, resistance to both have been detected46-51. 
Unfortunately, the rate of antibacterial discovery has slowed dramatically, and many big 
pharmaceutical companies have stopped developing new antibiotics.52-54 Based on a review 
article published in 2016,55 there are only 40 products in the antibiotic pipeline, compared 
to more than 120 compounds for treatment of non-small cell lung cancer and melanoma 
alone, for example.  
Antimicrobial resistance has enormous health and economic implications. It is estimated 
that antimicrobial resistance is directly responsible for 23,000 deaths annually in the United 
States56 and more than 25,000 in the European Union.57-58 A conservative estimate of the 
economic cost of bacterial resistance in the United States is $20 billion in healthcare costs 
and $35 billion in societal costs annually.59 Moreover, since antibiotics are often used as 
prophylaxis, resistance has the potential to lead us back to a pre-antibiotic world.60-61 For 
example, surgeries would become more dangerous. Economists have used hip 
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replacements as an example and estimated that the infectious rate would rise from 0.5-2% 
currently (with antibiotics) to 40-50% without effective antibiotics and 30% of patients would 
die.62 The most authoratative prediction of the impact of antimicrobial resistance was 
published in the Review on Antimicrobial Resistance by a team lead by the world-renowned 
macroeconomist Lord Jim O’Neill,63 former chairman of Goldman Sachs Asset Management, 
and former British government minister. He estimated that by 2050, based on the current 
rate of resistance and if no interventions take place, deaths from antimicrobial resistance 
could skyrocket to 10 million each year and cost $100 trillion globally. No other diseases 
except pandemic influenza can make such a claim. In fact, if the current trend is not altered, 
antimicrobial resistance could become the world’s single greatest killer, surpassing heart 
disease or cancer.64 
In 2013, the Centers for Disease Control and Prevention (CDC) published a list of 18 
drug-resistance threats to the United States.65 The list was further grouped into three 
different urgent categories: urgent, serious and concerning threats (Table 1). Three bacteria 
were listed in the urgent threat category: C. difficile, carbapenem-resistant 
Enterobacteriaceae and N. gonorrhoeae.65 The first two usually affect patients in medical 
facilities and/or those being treated with other antibiotics; however N. gonorrhoeae is a 
sexually transmitted disease that can infect healthy people.66-67 In early 2018, a man in the 
United Kingdom was diagnosed with a strain of N. gonorrhoeae that is resistant to all 
existing classes of antibiotics, perhaps the first occurrence of such an infection.68 The 
sexual transmission of these strains means that antibiotic resistance could spread much 
more rapidly. Twelve additional bacterial strains were grouped in the serious threat 
catogory.65 Among them are notorious bacteria such as multidrug-resistant Pseudomonas 
aeruginosa, methicillin-resistant S. aureus (MRSA), and drug-resistant M. tuberculosis. A 
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fungal infection, fluconazole-resistant Candida, was also included in the list. Candida is 
ranked 4th in a list of the most common hospital-acquired bloodstream infections,69 and it is 
estimated to cause more than 400,000 cases annually, mostly in developed countries.70 
Vancomycin-resistant S. aureus (VRSA) was in the concerning threat group.65 
Table 1. Drug-resistant threat to the United States. 
Threat level Microbes 
Urgent C. difficile 
Carbapenem-resistant Enterobacteriaceae 
Drug-resistant N. gonorrhoeae 
Serious Multidrug-resistant Acinetobacter 
 Drug-resistant Campylobacter 
 Fluconazole-resistant Candida 
 Extended specturm β-lactamase producing Enterobacteriaceae (ESBLs) 
 Vancomycin-resistant Enterococcus (VRE) 
 Multidrug-resistant Pseudomonas aeruginosa 
 Drug-resistant non-typhoidal Salmonella 
 Drug-resistant Salmonella Typhi 
 Drug-resistant Shigella 
 Methicillin-resistant Staphylococcus aureus (MRSA) 
 Drug-resistant Streptococcus pneumoniae 
 Drug-resistant tuberculosis 
Concerning Vancomycin-resistant Staphylococcus aureus (VRSA) 
 Erythromycin-resistant Group A Streptococcus 
 Clidamycin-resistant Group B Streptococcus 
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Clearly, the threat of infections from resistant micobes is real. There is an urgent and 
growing need for new antibiotics, particularly ones with novel mechanisms of action. One 
potential target for new therapeutics lies in the de novo purine biosynthetic pathway.  
1.2 Purine nucleotide biosynthesis 
Nucleotides play a variety of essential roles in cellular function. Most notably, they are 
the building blocks of DNA and RNA and act as carriers of chemical energy (ATP and to 
some extent GTP). Nucleotides are also components of cofactors such as NAD, FAD and 
coenzyme A and they can act as chemical messengers, such as cAMP and cGMP.71 The 
concentration of nucleotides in cells varies by its function and tissue type. The concentration 
of ATP concentration is quite high, while the cellular pools of other nucleotides are usually 
limited to less than that needed to synthesize 1% of the genome.71 Therefore, cells must 
constantly make nucleotides during rapid proliferation, suggesting that relevant biosynthetic 
enzymes may be logical targets against rapid dividing cells in diseases such as cancer and 
infections.72 Inhibitors against nucleotides biosynthesis, such as fluorouracil, methotrexate 
and mercaptopurine are valid and important chemotherapeutic and anti-viral agents.  
1.2.1 Salvage pathway71  
Given the critical nature of purine nucleotides to life, it is not surprising that there are 
two pathways for their synthesis: the de novo and the salvage pathways. De novo synthesis 
assembles nucleotides from basic metabolic precursors, including amino acids, ribose 5-
phosphate, CO2, and NH3 (Figure 1). The salvage pathways recycles free bases released 
from nucleic acid breakdown. Free adenine is salvaged by adenosine 
phosphoribosyltransferase which catalyzes the reaction of adenine with phosphoribosyl 
pyrophosphate (PRPP) to yield adenosine nucleotide. Free guanine and hypoxanthine are 
recycled in the same way by hypoxanthine-guanine phosphoribosyltransferase. These 
7 
 
 
salvage pathways play an important role in recycling nucleotides from the 
environment/tissue, and are usually considered necessary for maintaining cellular functions, 
while the de novo pathway is required for cell division. 
 
Figure 1. Precursors of inosine monophosphate used in de novo purine biosynthesis. PR 
is ribose phosphate. 
1.2.2 De novo pathway  
 In mammalian cells, the de novo synthesis of purines (Figure 2) starts from PRPP and 
takes 10 steps, while consuming 4 molecules of ATP. Microbes undergo a similar process 
except one additional energy-consuming step is necessary.73-75 Thus, in microbes, 11 steps 
are needed along with 5 molecules of ATP. The detailed pathway of purine biosynthesis 
was worked out primarily by John Buchanan and G. Robert Greenberg in the 1950s from 
isotopic tracing experiments.71 Atoms from basic precursors are connected to ribose 
phosphate creating the purine ring in a step-wise manner.  
In the first committed step, N-9 is connected to the sugar. An amino group, donated by 
glutamine, is attached to the C-1 position of PRPP yielding 5-phosphoribosylamine (PRA), 
a short-lived intermediate with a half-life of only 38 seconds at pH 7.5.76 In the second step, 
C-4, C-5 and N-7 are added onto the amino group of PRA from glycine, resulting in 
glycinamide ribonucleotide (GAR). ATP is used in this step to activate the glycine carbonyl 
group for condensation with the amine. Formylation of the amino group of GAR occurs in 
the third step to give N10-formyl glycinamide ribonucleotide (FGAR); this reaction adds C-8. 
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The fourth step converts the amide from the second reaction into an imine and adds N-3 by 
the addition of ammonia (from glutamine), while also consuming a molecule of ATP. The 
fifth step a is dehydration and ring closure reaction, yielding the five-membered ring, 
aminoimidazole ribonucleotide (AIR). This step requires ATP to activate the formyl group. 
At this point, the five-membered ring and three atoms of the six-membered ring (N-3, C-4, 
and C-5; C-4 and C-5 are shared between the two rings) are in place, requiring the addition 
of another two carbons and one nitrogen atom. C-6 is added in the sixth step, which 
represents a major difference between mammalian and microbial de novo purine 
synthesis.73-75 In mammals, carbon dioxide is added directly to the C-5 of AIR to generate 
carboxyaminoimidazole ribonucleotide (CAIR). In microbes, bicarbonate and ATP are used 
to add CO2 to the exocyclic amine of AIR (N-3) to generate N
5-carboxyaminoimidazole 
ribonucleotide (N5-CAIR). Rearrangement of the CO2 group from N-3 to C-5 later generates 
CAIR. A detailed description of this clade-specific divergence is provided in the following 
section.  The seventh and eighth steps add the last nitrogen (N-1) to the skeleton via an 
energy-consuming amide bond forming reaction between C-6 and aspartate amino group 
followed by the elimination of fumarate to give aminoimidazole-4-carboxamide 
ribonucleotide (AICAR). The final carbon, C-2, is contributed by N10-formyltetrahydrofolate. 
The last step is a second ring closure event, yielding the purine nucleus inosine 
monophosphate (IMP). IMP is then converted to GMP and AMP by subsequent enzymes. 
For clearness and simplicity, enzymes involved in de novo synthesis are not described 
in the text above. Abbreviations of the enzyme names are used in Figure 2 and throughout 
the following text. Full names of the enzymes are listed in Table 3. 
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Figure 2. De novo purine biosynthetic pathway. 
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Table 2. List of abbreviations of intermediates in de novo purine biosynthetic pathway. 
Abbreviations Full names 
PRPP 5-Phosphoribosylpyrophosphate 
PRA 5-Phospho-D-ribosylamine 
GAR Glycinamide ribonucleotide 
FGAR N-Formylglycinamide ribonucleotide 
FGAM N-Formylglycinamidine ribonucleotide 
AIR Aminoimidazole ribonucleotide 
N5-CAIR N5-Carboxyaminoimidazole ribonucleotide 
CAIR Carboxyaminoimidazole ribonucleotide 
SAICAR Succino 5-aminoimidazole-4-carboxamide ribonucleotide 
AICAR Aminoimidazole-4-carboxamide ribonucleotide 
FAICAR 5-Formamido-4-imidazolecarboxamide ribonucleotide 
IMP Inosine monophosphate 
 
  
11 
 
 
Table 3. List of abbreviations of enzymes in de novo purine biosynthetic pathway. 
Gene name Enzyme Abbreviations Enzyme Full names 
purF PurF Aminophosphoribosyltransferase 
purD PurD GAR synthetase 
purN PurN GAR transformylase 
purT PurT FGAR synthetase 
purL PurL FGAR synthetase 
purM PurM AIR synthetase 
purE (Class II) PurE Class II AIR carboxylase 
purK PurK N5-CAIR synthetase 
purE (Class I) PurE Class I N5-CAIR mutase 
purC PurC SAICAR synthetase 
purB PurB SAICAR lyase 
purH PurH AICAR transformylase 
purP PurP AICAR synthetase 
purJ PurJ IMP cyclohydrolase 
purO PurO IMP cyclohydrolase 
 
1.3 Divergences in the de novo pathway  
Several differences exist between prokaryotes and eukaryotes in the enzymes 
catalyzing the de novo pathway. These represent potential novel antimicrobial targets and  
are outlined and discussed in detail here.  
PurF: PurF catalyzes the first step in de novo purine synthesis, which is the conversion 
from PRPP to PRA. Structurally, two types of PurF have been found. The first is found in 
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higher vertebrates, plants, cyanobacteria, and Gram-positive bacteria, while the second is 
from yeast and Gram-negative bacteria.77-80 The main difference is that the first type 
contains a structural Fe4S4 cluster81 and a cleavable N-terminal propeptide, while the 
second does not. PurFs from B. subtilis82-83 and E. coli84-85 have been studied extensively. 
The two enzymes share 40% sequence identity and are structurally homologous. 
PurD: Only one known enzyme PurD catalyzes the second step, from PRA to GAR. In 
E. coli, it is a single enzyme, in higher organisms, however, PurD is fused with PurM and 
PurN forming a trifunctional enzyme.  
PurN/PurT: Two different enzymes catalyze the third, formylation step. PurN is found in 
most organisms and formylates the amino group using N10-formyltetrahydrofolate. In higher 
organisms, PurN is the C-terminal domain of the trifunctional enzyme PurD-PurM-PurN. 
Researchers have investigated human PurN as an anticancer target.86-92 E. coli can use an 
alternative enzyme PurT to catalyze this transition, and some archeabacteria have been 
found to rely solely on PurT. PurT is an ATP-grasp enzyme93-94 and catalyzes the ATP-
assisted ligation directly using formate as the carbon source.95-96 Being a redundant 
metabolic enzyme, PurT is generally not considered a therapeutic target. A recent study 
from Denmark however demonstrated that single-gene deletion of either purT or purN 
resulted in attenuation in Salmonella enterica serovar Typhimurium.97 This result suggests 
a revisit of the redundancy relationship of PurT and PurN is merited. 
PurL: Two different types of PurL have been found, termed large and small based on 
their respective sizes. Large PurL is found in eukaryotes and Gram-negative bacteria, while 
small PurL is found in Gram-positive bacteria and archaea.72, 98-99 Large PurL has three 
domains: the glutaminase, the FGAM synthetase, and the N-terminal domains. The 
glutaminase domain produces ammonia, which is then channeled to the FGAM synthetase 
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domain.100 The N-terminal domain helps to form the ammonia channel that links the other 
two catalytic domains.98 Small PurL only contains the FGAM synthetase domain and 
requires assistance from PurQ and PurS to complete its function.98, 101 PurQ is homologous 
to the glutaminase domain in large PurL,102 while PurS is similar to the N-terminal domain.103 
Recently, researchers have reconstructed the PurLSQ complex from B. subtilis and small 
molecules such as MgADP and glutamine have proved necessary for complex formation.99  
PurK, class I and II PurE (Figure 3): The largest divergence in the de novo purine 
synthesis pathway lies in the steps used to convert AIR to CAIR. Mammalian cells and 
microbes utilize different enzymes and different intermediates to complete this process.73-
75, 104 In vertebrates, it is a one-step conversion;74 however, two individual steps are needed 
in bacteria,73, 75, 104 yeast, and fungi.105 In human cells, AIR is carboxylated by class II PurE 
to CAIR directly utilizing CO2 as the carbon source.74, 105-107 No energy is needed in this 
transition. Mechanistically, direct carboxylation without co-factors such as biotin is unusual, 
and this step has attracted investigation from many researchers.108 In bacteria, yeast, and 
fungi, this conversion is broken down into two sequential steps. AIR is first converted by 
PurK to N5-CAIR using HCO3- as the one carbon source and consuming one molecule of 
ATP.75, 104 N5-CAIR then undergoes direct CO2 transfer from N5 to C4 to generate CAIR.109-
110 This second reaction is catalyzed by class I PurE. One type of bacteria however, the 
spirochete dental pathogen Treponema denticola, was found to contain a class II PurE with 
no PurK, and this is the first and only example of a prokaryotic class II PurE.111 
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Figure 3. Divergence between microbial and human de novo purine pathway. PR is ribose 
phosphate. 
Class I and II PurEs both form octamers in the native state,106, 110, 112-113 and their 
structures can be largely superimposed. They also share considerable sequence 
similarities. It is intriguing how these two almost identical enzymes catalyze distinct 
reactions. In human cells, class II PurE is fused with PurC to form a bifunctional enzyme.110 
A third type of PurE is found in archaea. Some methanobacteria have a purE-purE’ gene 
that encodes a 37 kDa polypeptide,114 twice the length of both Class I and II PurE. The C-
terminus half of the polypeptide can be aligned with its N-terminus half with 36% identity. 
Only the N-terminal half contains the universally conserved active site residues that exist in 
both class I and class II PurE, and its sequence can be characterized as a class I PurE by 
class-specific residues.115 Although sequence alignment suggests methanogens contain a 
class I PurE, the whole protein encoded by the M. thermoautotrophicum purE-purE’ gene 
has been purified and characterized to be a pure class II PurE utilizing AIR and CO2 as 
substrates without ATP.116 Complementary assays have been conducted on the M. smithii 
whole purE-purE’ gene and several truncated versions. Only the complete sequence can 
complement both PurK and PurE deficient E. coli strains; deletions of peptides of the length 
of 9 kDa, 25 kDa, 28 kDa and 30 kDa from the C-terminus, or even 7 amino acids at the 
15 
 
 
beginning of the C-terminus half abolished its ability to complement either PurK or PurE 
deficient strains.117-118 The methanogen PurE-PurE’ is the only identified PurE which may 
have an N-terminal PurE fused with other proteins. In other fused PurE system, such as the 
human bi-functional PurCE,74, 106 yeast bi-functional PurKE,105 the PurEs are all at the C-
terminus. No PurK homolog has been found in these organisms.  
In contrast with the three different types of PurEs, PurK is found only in microbes and 
does not have any human homologs. It is a separate enzyme in bacteria but fused with 
class I PurE as a bifunctional enzyme in fungi.105 PurK is a member of the ATP-grasp 
enzyme superfamily119-120 and it forms a dimer in its native state.121 
PurH, PurJ/PurP,PurO: Archaea use different enzymes in the last two steps compared 
to bacteria and eukaryotes. PurH and PurJ are found in bacteria and eukarya,122 while PurP 
and PurO occur in archaea.123 PurH catalyzes formylation of AICAR in a manner similar to 
PurN, using N10-formyltetrahydrofolate as a cofactor.124 In contrast, PurP is like PurT, 
catalyzing an ATP-assisted ligation of AICAR with formate.123 PurHJ is a bi-functional 
enzyme122, 125 and has been explored as an anticancer target.126-127 
1.4 Target verification of PurK 
Since the differences in the step from AIR to CAIR is divided strictly from mammalian 
cells to microbes, it is logical to explore PurK and microbial class I PurE as potential 
antimicrobial targets. There have been published studies on the development of inhibitors 
of both PurE128-129 and PurK.130 The development of PurE inhibitors is challenging because 
Class I and Class II PurEs are evolutionarily related. They each form an octamer in the 
native state, and their structures can be largely superimposed. They also share 
considerable sequence similarities complicating the discovery of class-specific inhibitors. 
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Indeed, the only known selective inhibitor of PurE shows selectivity for Class I over Class II 
PurE.108, 129 
PurK, on the other hand, does not have any human homologs. Therefore, it is more 
likely that selective antimicrobial agents targeting PurK could be identified. Genetic studies 
on PurK support the role of the enzyme in microbial growth and disease progression. In the 
1950s, Bacon described the loss of virulence of Bacterium typhosum mutants with purine 
synthesis deficiencies in a murine intraperitoneal infection model.131-133 Studies with 
different microorganisms, such as S. aureus,134 Bacillus anthracis,135 Candida albicans,136 
and Cryptococcus neoformans137 both in vivo and in vitro have given similar results. These 
results have also shown that the salvage pathway alone is not sufficient to produce enough 
purines for growth, validating the de novo purine pathway as an antimicrobial target. Taken 
together, both biochemical and genetical evidence support that PurK is an attractive 
antimicrobial target.  
1.5 Previous attempts at PurK inhibitor development 
Despite intensive biochemical and structural investigations of PurK, no one has 
developed selective inhibitors of this enzyme. To fill in this gap, our lab previously conducted 
a high-throughput screening study.130 Using a UV-based discontinuous assay measuring 
the free phosphate concentration in the system, we screened a 48,000 drug-like 
commercially available library. The screen identified 14 hits; however, additional studies 
revealed that none of these agents actually bound to PurK. Instead, 12 out of 14 agents 
covalently reacted with AIR.138 One compound was riboflavin, a vitamin, and several 
analogs of the last agent failed to give improved activity against the enzyme. Thus, a new 
approach towards identifying inhibitors against PurK was needed. This previous work forms 
the basis for this thesis.   
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1.6 ATP-grasp Family 
1.6.1 General introduction 
One approach towards finding inhibitors is to examine inhibitors of biochemically related 
enzymes. PurK belongs to the ATP-grasp enzyme superfamily.112, 121, 139-141 The ATP-grasp 
enzymes catalyze the ligation between an amino group and an activated carboxylate.119-120 
Activation requires one molecule of ATP to generate a proposed acylphosphate 
intermediate,142-143 though this intermediate has not been captured by crystallization. 
Enzymes within this family share a large degree of structural similarity among their ATP-
binding domains. In fact, the name of this group, ATP-grasp, is derived from the unique 
binding orientation of ATP in its ATP-binding site.  
Structurally, the ATP-grasp family is characterized by a three-domain architecture with 
A, B and C domains93 (Figure 4). The A and C domains form a central cleft where substrates 
reside.94, 144 The B domain holds ATP and is flexible upon nucleotide binding.123, 145 The 
polyphosphate group of the ATP is firmly bound to a conserved P-loop in the B domain and 
interacts with one to three Mg2+ ions.94 The high degree of topological similarity of the ATP-
binding domain is the signature of the ATP-grasp enzymes. 
 
Figure 4. General representation of the ATP-grasp enzymes based on the 3-D structure of 
the A. clavatus PurK enzyme (PDB ID: 3K5I). 
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Mechanistically, the ATP-grasp enzymes catalyze their reactions in a two-step 
fashion.146-148 First, the carboxylate is activated by ATP to generate an acylphosphate 
intermediate. Second, nucleophilic attack on the activated carbonyl group by the amino 
group occurs, eliminating free phosphate and resulting in the final ligation amide product.  
About 20 enzymes have been found to belong to this family. Four enzymes in the de 
novo purine biosynthetic pathway, PurD, PurT, PurK and PurP belong to this group, 
implying evolutionary significance.149 Other ATP-grasp enzymes play important roles in 
various critical metabolic pathways, such as fatty acid synthesis, gluconeogenesis and cell 
metabolism.119 Another member of this superfamily is biotin carboxylase (BC). BC catalyzes 
the first committed step in fatty acid synthesis, which is the ATP-dependent carboxylation 
of biotin using HCO3- as the one carbon source.150 Mechanistically, the first half reactions of 
BC and PurK are identical, namely the activation of bicarbonate by ATP to generate the 
putative common intermediate, carboxyphosphate151-152 (Figure 5a). The second reaction is 
the carboxylation of the substrate to generate the desired product and phosphate. Structural 
comparisons of both enzymes indicate that the ATP-grasp domains of PurK139-140, 153 and 
BC148, 154 can be largely superimposed (Figure 5b). Root mean square deviation (RMSD) in 
the aligned ATP-grasp regions is 1.609 Å, and the distances between the 6-NH2 and 2’-OH 
of the two aligned ADPs are 1.1 Å and 1.5 Å, respectively.  
a. Reaction 
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b. Structure 
 
Figure 5. Similarities between PurK and BC. a. Reaction similarity. b. Crystal structural 
superimposition of PurK (pdb: 3K5I, green) and BC (pdb: 2J9G, cyan) with ADP in the 
binding sites of both enzymes. 
1.6.2 ATP-site inhibitors of ATP-grasp family 
It has been estimated that about 9-10% of all enzymes bind ATP, and cells contain ATP 
in the millimolar range.155 It is no doubt challenging to develop selective inhibitors against a 
particular ATP-binding enzyme while also being able to compete against the high cellular 
concentration of ATP. However, kinase and phosphatase inhibitors are mainstream drugs 
for important diseases and demonstrate that these challenges can be overcome.156-158 In 
contrast, relatively few studies on inhibitors of ATP-grasp enzymes have been reported. 
However, one critical study came from Pfizer’s work on BC.159-160 
In a phenotypic HTS campaign,160 researchers from Pfizer focused on finding 
compounds that inhibited bacteria growth using a library of protein kinase inhibitors. A group 
of pyridopyrimidine compounds were found to possess potent antibacterial activity. The 
mechanism of action of these compounds was via inhibition of fatty acid synthesis 
specifically by targeting the ATP-grasp domain of BC. Investigations of additional analogs 
revealed a pyridopyrimidine (compound 1 Figure 6) with a Kd of 0.8 nM against purified E. 
coli BC with an IC50 of less than 5 nM in in vitro activity testing. X-ray crystallography studies 
ADP 
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confirmed that these pyridopyrimidines bound to the ATP-site of the ATP-grasp domain of 
BC. Researchers also confirmed the selectivity of these agents against other ATP-utilizing 
enzymes, demonstrating that the ATP-grasp domain was divergent enough for selective 
targeting over protein kinases. Encouraged by these results, follow-up studies159 were 
carried out using virtual and fragment-based methods, and additional ATP-site inhibitors 
with diverse scaffolds (Figure 6. The rest than compound 1) were identified. These 
pioneering proof-of-concept studies demonstrated that bacterial ATP-grasp enzymes could 
be selectively targeted over other ATP-utilizing enzymes and that these agents could be 
promising antimicrobial compounds. Inspired by the encouraging BC inhibitors published 
by Pfizer, a group of researchers from Slovenia and the UK tested the pyridopyrimidines 
against D-ala-D-ala ligase and demonstrated moderate inhibition activity.161   
 
Figure 6. ATP-binding site inhibitors of BC developed by Pfizer. 
At approximately the same time, a similar study from Schering-Plough was 
independently reported.162-164 Using an affinity-based assay coupled with mass 
spectroscopy, researchers identified a group of benzimidazole (Figure 7) compounds with 
low micromolar affinity against BC. Rapid hit-to-lead research resulted in the best 
compound possessing an IC50 of 20 nM with confirmed antibacterial activity. The authors 
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demonstrated that these compounds inhibit fatty acid synthesis but spare DNA, RNA, and 
protein synthesis. They also validated the target by using an E. coli strain sensitized to BC 
inhibitors by overexpression of apo-BCCP. These independent reports of distinct chemical 
classes of BC inhibitors demonstrate that the selective targeting of the ATP-grasp domain 
can be done and that these agents have the potential to be antimicrobial agents.  
 
Figure 7. ATP-binding site inhibitors of BC developed by Schering-Plough. 
Inspired by the reported high potency of ATP-site inhibitors of BC and the similarity 
between PurK and BC, we decided to test BC inhibitors to see if they provide a starting 
point to further develop selective PurK inhibitors. The results outlined below indicate that 
these agents can indeed be inhibitors of PurK, although with modest affinity when compared 
to BC.  Our results have also provided information on the binding of these agents to PurK.  
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CHAPTER 2 RESULTS AND DISCUSSIONS 
2.1 Preliminary testing of potent BC inhibitors against PurK 
2.1.1 Synthesis 
Three potent BC inhibitors (1, 2, and 3 in Figure 6) were selected to test as potential 
inhibitors of PurK. These compounds were selected because they are the most potent BC 
inhibitors in the Pfizer study and are either synthetically accessible (1 and 2) or 
commercially available (3). A fourth compound 4, 6-methylpyrido[2,3-d]pyrimidine-2,4-
diamine, was selected because it is commercially available and structurally similar to 
compound 3 and 1. To reduce the influences of the side chains only keeping the core 
scaffold, we deleted the dibromo substituents on the 6-pheny ring of compound 1. The 
dibromo compound was later tested as a derivative in section 2.3.2 as compound 11. 
Compounds and their numbers used in this preliminary test are listed in Figure 8.  
 
Figure 8. Compounds tested in the preliminary study. 
Compound 1 and 2 were made following literature methods159-161 from commercially 
available starting materials (Schemes 1 and 2). The approach outlines in scheme 1 gave 
the desired heterocyclic pyridopyrimidine starting from the pyrimidine ring. The pyrimidine 
was made by a ring formation reaction using commercially available starting materials 
guanidine nitrate and (ethoxymethylene)malononitrile. The nitrile group of 1a was readily 
reduced to aldehyde (1b) by Raney nickel in formic acid. The final pyrido[2,3-d]pyrimidine 
scaffold was prepared through a condensation reaction with benzyl nitrile. The approach 
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described in scheme 2 gave the second scaffold to be tested, methyloxazole carboxamide. 
This compound was made from the commercially available ethyl 2-methyloxazole-4-
carboxylate. Base hydrolysis revealed the carboxylic acid group, which was subsequently 
activated with HBTU and condensed with dibenzylamine to give the desired amide 2.  
 
Scheme 1. Synthesis of pyrido[2,3-d]pyrimidines. Reagents and conditions: (a) NaH, EtOH, 
-5 ºC to r.t., 18 h, 83%; (b) Ra-Ni, 98-100% HCOOH, reflux, 18 h, 89%; (c) NaH, 
EtO(CH2)2OH, reflux, 4 h, 84%. 
 
Scheme 2. Synthesis of methyloxazole-carboxamide. Reagents and conditions: (a) 2 M 
NaOH, 60 ºC, 45 min, 82%; (b) HBTU, NMM, DMF, r.t., 18 h, 20%. 
2.1.2 BC inhibitor pyrido[2,3-d]pyrimidine weakly inhibited PurKAsp 
We collected three potent BC inhibitors, 1, 2, 3, and another structurally related 
compound 4 and tested them against PurK from E. coli and A. clavatus (Table 4). Residual 
activities (RA%) were collected at a single inhibitory concentration, either 100 or 200 µM 
(depending upon solubility), using the malachite green assay we previously developed to 
monitor PurK activity.130 This assay is a discontinuous assay and measures the free 
phosphate concentration in a system. To compare inhibitory activity with the enzyme 
substrate ATP, adenine and adenosine were used as positive controls. Compounds 1 and 
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4 weakly inhibited PurK from A. clavatus whereas 2 and 3 were completely inactive at the 
concentrations tested. Compound 1 also exhibited weak inhibitory effect against PurK from 
E. coli. The enzymatic reaction time was optimized for different ATP concentrations to 
ensure the reaction stays in the linear range, and the assay was used for PurK kinetics with 
varied ATP concentration, while holding the concentration of AIR fixed. Steady state kinetics 
of 1 against PurK from E. coli confirmed that it is competitive with ATP and has a Ki of 255 
µM (Figure 9). These results validate that 1 binds to the ATP site of PurK as expected. 
Table 4. Activity of BC inhibitors against PurK.  
 
# Structure Conc. 
(µM) 
RA%     
PurKAsp 
RA% 
PurKE.coli 
1 
 
200 43 83 
2 
 
100 101 102 
3 
 
200 97 101 
4 
 
200 82 -- 
 Adenine 200 91 91 
 Adenosine 200 53 53 
-- Not tested. 
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Figure 9. Lineweaver-Burke plot of 1 against PurKE. coli using the  malachite green assay. 
The concentration of 1 (µM) is listed to the right of the graph. 
2.2 Computation studies suggested optimization positions 
While we expected that the BC inhibitors would not be as potent against PurK, we were 
puzzled by the ~250,000-fold weaker inhibitory activity of these inhibitors against PurK. 
Using a computational binding model generated by superimposition of the ATP-grasp 
regions of BC and PurK, we could propose theories explaining the decreased activity and 
potential positions for structural modifications to attempt to improve activity. We also 
examined the structures to identify the potential reasons why pyridopyrimidine 1 inhibited 
PurK from A. clavatus better than that from E. coli. Four X-ray structures were used in model 
generation: BC in complex with biotin, bicarbonate, ADP and Mg (PDB: 3G8C), BC in 
complex with pyrido[2,3-d]pyrimidine inhibitor 11 (PDB: 2V58), PurKAsp in complex with AIR, 
ADP and Mg (PDB: 3K5I), and PurKE. coli in complex with ADP and Mg (PDB: 1B6S).  
First, BC and PurKAsp in complex with ADPs were aligned to check for topological 
similarities. Chain A from each structure was used in the study. The sequences of ATP-
grasp domains  for BC and PurK were selected based on previous literature119 and selected 
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sequences are shown in Figure 11. The structural alignment (selection to selection) was 
carried out using PyMOL. Root mean square deviation (RMSD) in the aligned regions was 
1.609 Å (Figure 10). The distances between the 6-NH2 and 2’-OH of the two aligned ADPs 
are 1.1 Å and 1.5 Å, respectively. The key fingerprint residues in the ATP-binding sites are 
also aligned (Figure 10) and the ADP binding interactions are highly similar (Figure 12). 
 
Figure 10. Alignment of BC (PDB: 3G8C, green) and PurKAsp (PDB: 3K5I, cyan). The square 
highlights the ATP-grasp domain. Figure generated using PyMOL. 
 
Figure 11. Alignment and key fingerprint residues in the BC and PurKAsp ATP-grasp site. 
Residues in bold are conserved or similar residues involved in ATP binding. 
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Figure 12. 2-D illustration of the ATP binding interactions in BC (left) and PurKAsp (right). 
This diagram was generated using the ligand interaction plot as generated MOE. 
After confirmation of the structural similarities between the ATP-grasp domains of BC 
and PurKAsp, the X-ray structures of BC in complex with a pyrido[2,3-d]pyrimidine inhibitor 
11 (PDB: 2V58) was aligned to PurKAsp (PDB: 3K5I). RMSD in the aligned ATP-grasp 
regions was 2.01 Å. This direct structural superimposition resulted in the 6-phenyl and 2-
NH2 of the pyrido[2,3-d]pyrimidine clashing with the C-domain of PurKAsp (Figure 13, left). 
Energy minimization of the system resulted in a slight shift of the inhibitor (RMSD = 0.3 Å) 
to avoid the clashes and generate additional interactions with the protein (Figure 13, right).  
  
Figure 13. 2-D illustration of the pyrido[2,3-d]pyrimidine inhibitor 11 binding interactions 
with the ATP-binding site of PurKAsp (PDB: 3K5I). Left: direct structure superimposition of 
BC and PurKAsp. Right: Energy minimization of inhibitor 11 and PurKAsp. 
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This ligand interaction diagram (Figure 13 right) thus forms the hypothetical binding 
model for pyrido[2,3-d]pyrimidines binding to PurK. A couple of assumptions are made with 
this model and its use. First, the weaker inhibitory activity of 1 against PurK compared to 11 
against BC was not due to the dibromo substitutions on the 6-phenyl ring. Thus, the binding 
model of 11 in the ATP-site of PurK represents 1 in the same place. (This assumption was 
later proved correct in section 2.3.2.) Second, the pyrido[2,3-d]pyrimidine compound binds 
in the same location and orientation in the ATP-site of PurKAsp as in the ATP-site of BC. 
Without direct structure evidence, it is difficult to evaluate the accuracy of this assumption. 
Despite the hypothetical nature of the model, it reveals some information regarding how 
the pyrido[2,3-d]pyrimidine compounds interact within the ATP-site of PurKAsp. First, the key 
residues that contribute to the adenine-binding in the ATP-site also play important roles in 
binding with pyrido[2,3-d]pyrimidines (Figure 14). This makes sense considering pyrido[2,3-
d]pyrimidine is a nitrogen-containing heterocycle similar to adenine. Ala184 contributes a 
H-bond donor to both the N-1 in adenine and the N-3 in pyrido[2,3-d]pyrimidine. Glu181 and 
Lys182 provide H-bond acceptors to the 6-NH2 and 2-NH2 in adenine and pyrido[2,3-
d]pyrimidine, respectively. Lys146 donates H-bonds to the N-7 in adenine and N-1 and N-
8 in pyrido[2,3-d]pyrimidine. Among these four residues, Lys146 and Glu181 are conserved 
fingerprint residues among all ATP-grasp enzymes. Although Lys182 is not conserved 
among the enzymes of the ATP-grasp family in general, BC happens to possess a lysine 
residue at the corresponding position, Lys202.  
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Figure 14. 2-D illustration of the proposed binding orientation of pyrido[2,3-d]pyrimidine 
overlapping with ADP in the ATP-site of PurKAsp. Interactions with inhibitors were shown in 
green, while interactions with ADP were shown in red. 
Second, despite the proposed six H-bond interactions between pyrido[2,3-d]pyrimidine 
with the adenine-binding regions in the ATP-site of PurKAsp, few interactions were found 
between either the ribose or the phosphate binding domains and the pyrido[2,3-d]pyrimidine. 
In fact, we believe the limited interactions between these domains and the compound could 
explain the large difference in activity of the pyrido[2,3-d]pyrimidines between  BC and 
PurKAsp. In BC, stacking interactions are found between His236 and His438 with the 
substituted phenyl ring of the compound, and key hydrophobic interactions are also found 
between this ring and Ile437 (Figure 15). In the Pfizer study of pyrido[2,3-d]pyrimidines 
inhibiting BC160, a I437T mutant renders 11 more than 112-fold less active compared to the 
wild-type enzyme (IC50 of 560 nM vs 5 nM) while a H438P mutant results in a more than 
32-fold decrease in activity (IC50 160 nM vs 5 nM). In PurKAsp, the residue corresponding to 
His236 is Ser214, and other than an analogous H-bond acceptor toward 7-NH2, no 
corresponding stacking or hydrophobic interaction with the 6-phenyl ring was identified. 
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PurKAsp is also shorter in its C-terminus compared to BC (Figure 16) and thus there is a loss 
of the analogous hydrophobic contacts between the enzyme and the substituted phenyl ring. 
The decreased length of the C-terminus, in turn, makes the ATP-binding site more spacious 
in PurKAsp resulting in a decrease in shape complementarity between the inhibitor and the 
binding pocket.  
 
Figure 15. 2-D illustration of the pyrido[2,3-d]pyrimidine inhibitor 11 binding interactions 
with the ATP-binding site of BC (PDB: 2V58). 
 
Figure 16. Crystal structural superimposition of PurK (pdb: 3K5I, green) and BC (pdb: 2V58, 
yellow) with pyridopyrimidine 11 in the binding site. The orange circle highlights the 
additional C-terminus of BC, and the arrow points to the PurK C-terminus end. 
I437 
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A similar method was applied to search for the potential explanations of the relatively 
poor inhibitions of pyrido[2,3-d]pyrimidine against PurKE. coli compared to PurKAsp. A 
structural alignment was conducted between BC and PurKE. coli (RMSD 7.10 Å) and PurKAsp 
with PurKE. coli (RMSD 5.46 Å). There were a few features that were noted in this comparison.  
First, the ATP-site of PurKE. coli is more open than PurKAsp (Figure 17) resulting in a greater 
loss of shape complementarity. Second, Trp183 in PurKAsp could contribute to a stacking 
interaction with the heterocycle core in pyrido[2,3-d]pyrimidine. The corresponding residue 
in PurKE. coli is Gly155 which lacks the ability for π-stacking (Figure 18). Finally, despite the 
poor predictive outcome of the calculated binding energy, forcefield calculations indicated 
that the calculated affinity for the system was -5.5 kcal/mol, worse than that of 11 and 
PurKAsp. Due to the poor inhibition against PurKE. coli, pyrido[2,3-d]pyrimidines are less ideal 
hits for antibacterial than antifungal drug development. All further activities were measured 
against PurKAsp only. 
  
Figure 17. Surfaces of the ATP-site for PurKE. coli (left) and PurKAsp (right). Molecular 
surfaces are colored by atom color with blue for nitrogen, red for oxygen, yellow for sulfur 
and grey for the carbon backbone. 
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Figure 18. Crystal structural superimposition of PurKAsp (pdb: 3K5I, green) and PurKE. coli 
(pdb: 3ETJ, cyan) with pyridopyrimidine (purple) aligned in the ATP-site. The PurKAsp 
residue W183 could form stacking interaction with the heterocycle, while correspondingly 
G155 resides in PurKE. coli. 
The hypothetical binding model suggests further regions on the pyrido[2,3-d]pyrimidine 
that could be modified to improve the activity. The model shows that there are extensive 
hydrogen bonding interactions of the pyrido[2,3-d]pyrimidine heterocycle with residues in 
the adenine position of the ATP-site; however, there are no obvious interactions between 
the molecule and the protein within the ribose and triphosphate binding sites. This 
suggested that modifications of the pyrido[2,3-d]pyrimidine at the 6-phenyl and 7-amine 
positions might generate interactions with amino acids in the ribose and triphosphate sites 
leading to pyrido[2,3-d]pyrimidine analogs with higher potency (Figure 19).  
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Figure 19. Modification strategy. 
2.3 Ribose-binding position (R1) modifications 
2.3.1 Synthesis 
Based on the model from the structural alignment with BC, the 6-phenyl group sits in 
the ribose binding site. Thus, we prepared a series of compounds in which various 
substitutions on the 6-position (R1 in Scheme 3) were generated. Synthesis of these agents 
(5-23) was conducted by condensation of aldehyde 1b and nitriles to make pyrido[2,3-
d]pyrimidine derivatives with various groups at the 6-phenyl position (Scheme 3). Nitriles 
with an aliphatic R1 were used for compounds 5 to 8 whereas substituted benzyl nitriles 
were used for compounds 9 to 20, and nitriles in which R1 contained of heterocycles were 
used for compounds 21 to 23.  
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Scheme 3. Synthesis of pyrido[2,3-d]pyrimidines with various substitutions at the 6-
phenyl position. Reagents and conditions: (a) NaH, EtO(CH2)2OH, reflux, 4 h, 11-84%. 
2.3.2 Biological evaluations  
We examined a series of substituted 6-phenyl analogs at a single concentration (200 
µM) using the malachite green PurK assay. For analogs displaying better inhibition than 1, 
IC50 values were determined using the malachite green assay as well as a secondary 
PK/LDH coupled PurK assay. This assay couples PurK to pyruvate kinase (PK) and lactate 
dehydrogenase (LDH) and use changes in the absorption of NADH as a measure of ATP 
consumption. 
Three groups of variances were explored at the R1 position. The 6-phenyl was first 
replaced by smaller substitutions (compound 5-8), due to a lack of obvious interactions 
between the phenyl and PurKAsp. Each compound displayed weaker activity than the parent 
agent. This implies that the 6-phenyl group may have unrecognized hydrophobic or 
aromatic interactions or that it may help to orient the pyrido[2,3-d]pyrimidine heterocycle 
into the adenine site. Indeed, minimization of molecular models of 5 indicate that there is a 
substantial loss of interaction of the pyridopyrimidine with the adenine site due to movement 
of 5 into the ribose binding pocket. We subsequently explored different substitutions on the 
phenyl ring. Small substitutions at the 2 and 6 positions improved activity whereas large 
groups decreased activity. Notably, the most active BC inhibitor, compound 11, only 
exhibited 23% inhibition at 200 uM against PurKAsp and was worse than the parent 
compound 1. This is interesting since 11 is a potent inhibitor of BC and this reemphasizes 
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the difference among the ATP-grasp domains of enzymes within the same superfamily. 
Substitutions at the 3 and 5 positions decreased activity significantly, except for the diol 
substitutions, 14. This compound nearly inactivated PurKAsp at 200 uM, and subsequent 
studies indicated an IC50 of 14 µM, a nearly 12-fold improvement from 1. The PK/LDH 
coupled PurK assay was used to investigate the inhibition kinetics of 14. This study 
indicated that 14 is competitive with ATP and has a Ki of 7.9 ± 1.6 µM against PurKAsp 
(Figure 20). This activity increase offered by polar substitutions fit well with the hypothetical 
binding model in which 6-phenyl sits in the ribose-binding site. Finally, we tested several 
heterocycles and found that the phenyl ring appears to be the optimal option. 
Table 5. Ribose position (R1) modifications. 
 
# R1 RA% 
200 µM 
IC50 
Malachite 
green assay 
IC50 
PK-LDH 
assay 
1 
 
43 167±16 97±16 
5  73 - - 
6  98 - - 
7 
 
64 - - 
8 
 
58 - - 
9 
 
21±2 41±7 38±9 
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10 
 
24±1 40±11 58±9 
11 
 
77 - - 
12 
 
71 - - 
13 
 
117 (100 µM) - - 
14 
 
3 14±2 15±1 
15 
 
75 - - 
16 
 
47 - - 
17 
 
88 (100 µM) - - 
18 
 
NA - - 
19 
 
58±7 - - 
20 
 
78±4 - - 
21 
 
65±8 - - 
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22 
 
51±5 - - 
23 
 
75±4 - - 
 
 
Figure 20. Lineweaver-Burke plot of 14 against PurKAsp using the PK/LDH coupled PurK 
assay. The concentration of 14 (in µM) is listed to the right of the graph. The experiment 
was done at an AIR concentration of 25 µM. 
2.4 Phosphate-binding position (R2) modifications 
2.4.1 Synthesis 
Two types of derivatives were explored at the phosphate (R2) position, N-alkylation (or 
O-alkylation) and urea substitutions. These two groups were selected based on  two 
reasons: synthetic feasibility and improved activity in other ATP-utilization enzymes, such 
as kinases165-171. N-alkylation (24-35) and O-alkylation (36, 37) were achieved through the 
critical intermediate 1e, 7-chloro-6-phenylpyrido[2,3-d]pyrimidin-2-amine. To achieve this 
intermediate, the amine group of compound 1 was first hydrolyzed to the alcohol (1c) under 
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acidic condition followed by chlorination using thionyl chloride. Once the chloro-
pyridopyrimidine (1e) was obtained, the chlorine atom was readily displaced by either 
amines (24-35) or alcohols (36, 37) (Scheme 4). Urea substitutions (38-50) were introduced 
by direct reaction of the amines with isocyanate under basic conditions (Scheme 5). 
 
Scheme 4. Synthesis of pyrido[2,3-d]pyrimidines with various N/O-alkylations at the 7-NH2 
position. Reagent and conditions: (a) 8 M HCl, reflux, 24 h, 62%; (b) SOCl2, DMF, CH2Cl2, 
mw, 45 ºC, 1 h, 78%; (c) 95 % EtOH, reflux, 8 h, 57%; (d) DIPEA, DMF, 100 ºC, 45%; (e) 
MeOH, reflux, 95%. 
 
Scheme 5. Synthesis of pyrido[2,3-d]pyrimidines with various ureas at the 7-NH2 position. 
Reagent and conditions: (a) NaH, DMF, r.t., 12h, 15-42%. 
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2.4.2 Biological evaluations.  
Based on the hypothetical model, the 7-NH2 points to the triphosphate binding site. Two 
types of derivatives were explored at this position, N-alkylation (or O-alkylation) and urea 
substitutions. These two groups were selected based upon synthetic feasibility and their 
abilities to improve inhibition in other ATP-utilizing enzymes. Activities were measured as 
described in the previous section. 
For alkylation derivatives, cyclic (24-29), chain (30-35) and two O-alkylates (36, 37) 
were explored. In the cyclic group, decreasing ring size improved activity indicating that 
there is a small hydrophobic pocket at this location. Moderate activity increases were 
achieved by the pyrrolidine (27) and cyclopropane (29) substitutions. Significant 
improvement in activities were reached in the chain group (30-35). Simply decreasing the 
polarity by one or two small alkyl substitutions (30-33) improved the activity 2-4-fold which 
indicated the existence of a small hydrophobic pocket. A polar group at the end of this alkyl 
chain also improved activity with a 3-carbon length (34) showing better activity than a 2-
carbon one (35). No significant change in activity was achieved by the O-alkylated 
compounds, 36 and 37.  
All the urea substitutions decreased activity and led to significant solubility issues. This 
was surprising given their wide utilization in kinases inhibitors. Again, these differences 
suggest the fundamental uniqueness in the ATP-binding sites of the ATP-grasp proteins 
versus the protein kinases.  
Table 6. Phosphate position (R2) modifications. 
 
 R2 RA% IC50 IC50 
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200 µM phosphate 
assay 
 
PK-LDH 
assay 
1  43 167±16 97±16 
24 
 
42±2 (100 
µM) 
75±15 81±3 
25 
 
36 - - 
26 
 
43±3 116±12 - 
27 
 
31±2 90±5 68±3 
28 
 
48±5 - - 
29 
 
25±1 - - 
30 
 
18±1 39±2 33±5 
31 
 
21±1 - - 
32 
 
38±3 69±7 71±9 
33 
 
21±1 42±4 - 
34 
 
19±1 24±5 37±2 
35 
 
35±1 91±10 - 
36  46 - - 
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37 
 
69±5 (100 
µM) 
- - 
38 
 
-- - - 
39 
 
65 (50 µM) - - 
40 
 
76 (50 µM) - - 
41 
 
83 - - 
42 
 
88 (26 µM) - - 
43 
 
90 (50 µM) - - 
44 
 
69 (100 µM) - - 
45 
 
-- - - 
46 
 
86 (26 µM) - - 
47 
 
69 - - 
48 
 
70 - - 
 
42 
 
 
Table 6. Cont. 
49 
 
88 - - 
50 
 
86 - - 
 
 
2.5 Double modifications 
2.5.1 Synthesis 
When we decided to combine both the R1 and R2 modifications to make the double 
modified pyrido[2,3-d]pyrimidines, we first tried reactions similar to those listed in Scheme 
4.  The analogous critical intermediate to 1e was 7-chloro-6-(3,5-
dimethoxyphenyl)pyrido[2,3-d]pyrimidin-2-amine. Unfortunately, this initial approach failed 
to give this intermediate presumably due to the instability of methoxy groups under acidic 
conditions (Scheme 6). In fact, even the first hydrolysis reaction of converting the amine to 
the alcohol group gave a majority of mono-demethylated product.  
 
Scheme 6. The failed synthesis for the key intermediate of the double modified compounds. 
Reagent and conditions: (a) 8 M HCl, reflux, 3 h, 21%. 
After retrosynthetic analysis, we decided to investigate a different route. Instead of 
assembling the pyrido[2,3-d]pyrimidines from the pyrimidine ring as in the previous 
schemes, we set out to make the pyridine ring first (Scheme 7).  
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The critical intermediate in this new synthetic route is 2,6-difluoro-5-iodonicotinaldehyde, 
7c. This intermediate contains three handles needed for the synthesis of the final product. 
Compound 7c contained a 2-fluorine and 3-aldehyde which enables cyclization with 
guanidine to yield the pyrimidine, a 5-iodine which is necessary for aryl-aryl coupling via a 
Suzuki reaction, and a 6-fluorine which enables N-substitutions. The only published protocol 
for the synthesis of 7c was a patent method which produced the compound from 
commercially available  2,6-difluoro-3-pyridinecarboxaldehyde172. Unfortunately, details in 
the patent were limited which led to difficulty with the iodination reaction (step b in Scheme 
7).  Ultimately, we found that after generating the anion by LDA deprotonation, the iodine 
solution needed to be added slowly during a span of at least 2 hours to ensure a consistent 
and optimum yield.  
After obtaining the critical intermediate 7c, we tried the subsequent three reactions 
toward the final products: cyclization, Suzuki reaction and N-substitution reaction. 
Compound 7c failed to undergo direct Suzuki coupling presumably due to the interference 
of the aldehyde. The cyclization reaction on 7c also failed likely because of competition 
reactions at the two fluorines in the molecule.   
Gaining inspiration from the chemoselective reactions of 3-substituted-2,6-
difluoropyridines with benzylamine173, we tried to react 7c with 3-
(dimethylamino)propylamine directly and obtained 7d in a reasonable yield. No reaction at 
the 2-position or Schiff base were observed.  This intermediate 7d readily underwent 
cyclization followed by Suzuki coupling to give a series of double-modified compounds (51-
57).  
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Scheme 7. Synthesis of pyrido[2,3-d]pyrimidines with double modifications. Reagents 
and conditions: (a) triethyl orthoformate, PTSA, EtOH, reflux, 18 h, 83%; (b) I2, LDA, THF, 
-78 ºC , 2 h, 96%; (c) HCl, THF/H2O, r.t., 4 d, 96%; (d) 3-(dimethylamino)propylamine, 
K2CO3, DMSO, r.t., 2 h, 78%; (e) guanidine nitrate, TEA, MeCN, mw, 150 ºC, 1 h, 33%; 
(f) Pd(PPh3)4, Na2CO3, MeCN/DMF/H2O, 90 ºC, 6 h, 45-68%. 
2.5.2 Biological evaluations. 
Examination of compounds with modifications in the ribose (R1) or triphosphate (R2) 
binding sites resulted in compounds (14 and 34) with improved activity. Thus, it was logical 
to explore agents in which both sites were substituted with the best substituent. Together 
with the exact combination of 14 and 34, we also explored a few other substituents on the 
phenyl ring. Due to synthetic limitations, only one N-alkylation substituent was explored at 
the R2 position. 
Double-modified compounds indeed combined the activity gain of each modification. 
Interestingly, cyclohexene substituted 55 has similar activity with phenyl 34, while 
cyclohexane 57 decreased activity. Both indoles, 53 and 54, improved activity with 53 better 
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than 54. The most active compound 56 – directly merging 14 and 34 – has an IC50 of 1.7 
µM. This is 100-fold improvement from the parent hit 1, and the most active ATP-site PurKAsp 
inhibitor to date.  
To confirm binding affinity, we developed a thermal shift assay128, 174-175 for PurK. To 
develop the condition of thermal shift assay for PurK, 1 mM ADP was used as the positive 
control to optimize the buffer type, concentration, pH and salt additives. The condition in 
which ADP achieved the largest shift of the protein melting point was selected as the 
optimized condition. We examined a range of buffers including 50 mM Tris (pH 8.0), 50 mM 
HEPEs (pH 8.0), 50 mM sodium phosphate (pH 8.0), 50 mM MOPS (pH 8.0) and 50 mM 
MES (pH 6.5). MES was selected and further tested for optimal pH from 5.5 to 8.0 in 0.5 pH 
interval. A pH 6.0 was selected followed by the optimization of the MES concentration. 
Three different concentrations were tested, 20 mM, 50 mM and 100 mM, and 20 mM 
achieved the maximum thermal shift for ADP. Finally, NaCl was tested as an additive (0, 50 
mM and 250 mM) and it was found that no salt achieved the best melting curve. The 
optimized condition was 20 mM MES buffer, pH 6.0. Under this condition, 1 mM ADP 
achieved a 7.2 ± 0.5 ºC shift of the PurK melting point. Using the optimized condition, we 
validated the binding of 1 and 56 (Figure 21) giving a Kd of 117.2 ± 53.9 µM and 9.0 ± 1.7 
µM. The low accuracy for the Kd of 1 is likely because of the inability to measure melting at 
higher concentrations due to solubility issues. This prevents the reaching of a plateau 
reducing the accuracy of the curve fit.  
Table 7. Double modifications.  
 
# R1 R2 RA% IC50 
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200 µM phosphate 
assay 
34 
  
19±1 24±5 
51 
 
 
72±4 - 
52 
 
 
38±2 - 
53 
 
 
6±0.4 6.1±0.6 
54 
 
 
12±1 - 
55 
  
20±1 - 
56 
 
 
3.1±0.2 1.7±0.2 
57 
  
32±2 - 
58 
  
86 (26 
µM) 
- 
59 
  
28 (100 
µM) 
- 
60 
  
60 (26 
µM) 
- 
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Figure 21. Binding affinity of compound 1 and 56 against PurKAsp as measured by the thermal 
shift assay. 
2.6 1,6-naphthyridines and 1,8-naphthyridines 
2.6.1 Synthesis 
Previously, we have discovered that pyrido[2,3-d]pyrimidine weakly inhibited PurKAsp, 
and through modifications of the 6-phenyl and 7-NH2 positions we were able to obtain 
compounds with better inhibitory activity. To study the functions of the aza atoms of the 
pyridopyrimidine moiety in interacting with PurKAsp, we synthesized two small groups of 
compounds containing 1,6-naphthyridine and 1,8-naphthyridine, respectively (Figure 22). 
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The knowledge of the heteroatoms’ contributions in affinity not only extends the SAR of the 
pyridopyrimidine core, but also helps to evaluate the computational binding model between 
PurKAsp and the pyridopyrimidine compounds.  
 
Figure 22. Structures of pyrido[2,3-d]pyrimidine, 1,6-naphthyridine and 1,8-naphthyridine. 
Both 1,6-naphthyridines and 1,8-naphthyridines were made using similar approaches 
as that for pyrido[2,3-d]pyrimidines in Scheme 1. In short, the heterocycle was obtained by 
a condensation reaction between a molecule possessing both an amine and an aldehyde 
group ortho to the amine and different acetonitriles (Scheme 8 and 9).   
The precursor for 1,6-naphthyridines, 4,6-diaminonicotinaldehyde (8c), was made from 
the commercially available 2-amino-1,1,3-propenetricarbonitrile using a three-step 
published method176-178. Condensation reactions between 4,6-diaminonicotinaldehyde and 
different acetonitriles resulted in the corresponding 1,6-naphthyridines (Scheme 8). The 
precursor for 1,8-naphthyridines, 2,6-diaminonicotinaldehyde (9a), was made from pyridine-
2,6-diamine using a published method179, and similar condensations with acetonitriles gave 
the desired1,8-naphthyridines (Scheme 9). In both cases, we chose R1 groups based upon 
the activity of the parent pyridopyrimidine compounds outlined in previous tables.  
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Scheme 8. Synthesis of 1,6-naphthyridines. Reagents and conditions: (a) HBr/HOAc, r.t., 
18 h, 79%; (b) H2, 10% Pd/C, NaHCO3, MeOH, 15 psi, 6 h, 42%;(c) Ra-Ni, 98-100% 
HCOOH, reflux, 24 h, 34%; (d) NaH, EtO(CH2)2OH, reflux, 2-24 h, 13-96%. 
 
Scheme 9. Synthesis of 1,8-naphthyridines. Reagents and conditions: (a)NaOH, CHCl3, 
ethanol, reflux, 18 h, 29%; (b) NaH, EtO(CH2)2OH, reflux, 3-7 h, 19-87%. 
2.6.2 Functions of the aza atoms in pyridopyrimidine 
The activity of the 1,6-naphthyridines and 1,8-naphthyridines against PurKAsp were 
evaluated at a single concentration of 200 µM using the malachite green phosphate assays 
(Table 8). Compared with the parent pyridopyrimidines, all 1,8-naphthyridines completely 
lost activity indicating that the N-3 forms crucial interaction within the PurKAsp active site. 
The 1,6-naphthyridines generally possessed small to modest reductions in activity 
compared to the parent compounds. Compounds bearing the 2,6-F and 3,5-OCH3 
substituents were essentially as active as the pyridopyrimidines while other substitutions 
generally lost about 20% of their potency.  This data suggests that unlike N-3, N-1 is not 
critical for binding to the enzyme.   
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Table 8. 1,6-naphthyridines (left), 1,8-naphthyridines (middle) and the parent 
pyridopyrimidines (right). 
# RA% 
 
# 
 
# 
 
62 
 
68±2 67 98±7 1 43±2 
63 
 
57±2 68 92±6 10 24±1 
64 
 
14±1 - - 9 21±2 
65 
 
77±5 69 84±4 19 58±7 
66 
 
77±4 70 94±3 15 75±4 
 
2.7 Development of binding models to PurKAsp for pyrido[2,3-d]pyrimidine inhibitors 
In this thesis, we have identified a group of pyrido[2,3-d]pyrimidine containing 
compounds as PurKAsp ATP-competitive inhibitors.  Modifications were made at the N-1, N-
3, C-6, and C-7 positions and the resulting compounds were utilized to determine a 
structure-activity relationship (SAR). To understand the structural basis for their potency 
and selectivity and to rationalize the observed SAR to benefit future structural-based 
optimization efforts, we were interested in developing a computational binding model of 
these compounds against PurK. Two different approaches were taken to generate models. 
The first took advantage of the structural similarities among the ATP-grasp domain proteins 
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and the extensive ligand: enzyme crystal structures for some of these enzymes, while the 
second utilized docking to generate hypothetical binding models. 
2.7.1 Binding model based on structural alignment 
The construct of this model was described in section 2.2 (Figure 23). This model was 
built from structural superimposition of the crystal structures of PurK and BC. Based on the 
interactions found in this model, we decided to explore structural modifications of the 6-
phenyl and 7-NH2 positions. Each position gave a full range of SAR with both improved and 
decreased activity ranging at least two magnitudes in the differences in IC50. This change 
in SAR verified the suitability of these two positions for medicinal chemistry optimization. In 
this section, we evaluate whether this model could explain the SAR obtained from our 
studies.  
 
Figure 23. The hypothetical binding model generated by structural superimposition of 
PurKAsp (pdb: 3K5I) and BC (pdb: 2V58). 
First, we examined whether the proposed H-bond interactions in the model are 
supported by the SAR observed by the two groups of naphthyridine compounds. Based on 
the model, N-3 forms a critical interaction with Ala184, while N-1 and N-8 share an 
interaction with Lys146. Due to synthetic limitations, we did not convert the N-8 in 
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pyrido[2,3-d]pyrimidine to C to make a group of quinazolines; however, we expected the 
quinazolines would have similar activity to 1,6-naphthyridines. These results indicate that 
N-3 forms a critical binding interaction while the bifurcated nature of the H-bond to Lys146 
indicates that removal of the N-1 was not detrimental to the activity.  This suggests that the 
H-bond interaction to Lys146 is not critical for binding to the enzyme. 
We next wished to test the validity of the binding model based on the SAR of the 6-
phenyl and 7-NH2 modified compounds. The calculated binding affinity of the compounds 
were plotted against the percent residual activity to determine whether the calculated 
binding affinity based upon the model could accurately predict the potency of the inhibitors.  
PurKAsp was prepared using the QuickPrep function in MOE which checks the structure 
for completeness and protonation state. Non- active-site water molecules, defined as waters 
farther than 4.5 Å away from ligand, were deleted. Residues that are 8 Å away from ligand 
were fixed during minimization. Forcefield energy minimization was terminated when the 
RMS gradient fell below 0.1 kcal/mol/Å. Each compound was placed into the model using 
the same orientation and location as 11, and energy minimization was performed to 
calculate potential affinity180.  
Figure 24 summarized the calculated affinity (kcal/mol) vs. experimental %RA of all 
compounds that were tested at 200 µM. Linear regression was performed resulting in an R2 
of 0.22, suggesting that the predictive ability of the binding model is poor. The binding model 
also failed to predict that compound 14 and 34 were the most active derivatives at the C-6 
and N-7 positions respectively. However, when the data was separated by the modification 
position and indicated in different colors, the calculated affinity was generally the largest for 
C-6 modifications (orange) and smallest for the double modifications (blue) with the N-7 
modifications (grey) in between. This general trend agrees with their relative activity shown 
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in the experimental test. With a few exceptions (9, 10, and 14), the C-6 modifications did 
not improve activity, while most N-7 non-urea modifications gave more active compounds, 
and the double modified compounds were able to combine the activity gain of each position. 
Most N-7 urea modifications had solubility limitations at 200 µM, and therefore were not 
included in the graphic analysis. However, an examination of the calculated binding affinity 
of the urea substituted compounds indicated that these compounds were poor binders due 
to clashes with PurKAsp, a result supported by experimental evidence. 
 
Figure 24. Correlation of calculated affinity (kcal/mol) vs. experimental %RA. Different 
modifications are represented by different colors: orange for C-6 modifications, grey for 
N-7 modifications, and blue represents the double modifications 
There are several potential reasons why the calculated affinity is in poor correlation with 
experiment %RA. First, the original assumptions made in the model (pyrido[2,3-d]pyrimidine 
binds the active site of PurK the same as in BC, and all pyrido[2,3-d]pyrimidines bind in the 
ATP-site in the same orientation as the parent compound 11) are inaccurate. Second, the 
binding energy calculations do not consider the issue of desolvation energy upon binding 
to the enzyme. Third, the protein structure is rigid in the forcefield calculation and fails to 
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represent the real protein structure. Fourth, there could be structural water molecules that 
are necessary for binding and these are not included in the model or the energy calculations.  
2.7.2 Binding model based on docking studies 
While the binding model generated by structural alignments could provide some 
information on the interactions between the ligand and the enzyme, the model gave a poor 
correlation between the calculated binding energy and the observed potency. While other 
factors explained in the previous section could provide an explanation for the poor 
performance, we felt that the initial assumptions of the model could be incorrect. Namely, 
we were concerned that the pyrido[2,3-d]pyrimidine might not bind to the ATP-site of PurK 
in the same orientation as in BC and consequently, we were also worried that different 
derivatives of the compounds may adopt different binding orientations within the more open 
ATP-binding site of PurK. Studies on the ATP-site inhibitors of kinases suggested that 
derivatives of the same scaffolds could indeed bind the active site in different orientations181. 
To eliminate the bias of the orientation provided by the alignment to the structure of the 
ligand:BC complex, we conducted docking studies to explore other binding models.  
Docking studies were done using chain A of PurKAsp in complex with AIR, ADP and Mg 
(PDB: 3K5I). The crystal structured was corrected and prepared using the MOE Structure 
Preparation application, the hydrogen bond network was optimized through Protonate 3D, 
and charges were calculated via Partial Charges. Since pyrido[2,3-d]pyrimidine was 
confirmed as an ATP-competitive inhibitor in our kinetics analysis, the binding site was 
specified as the ATP-binding site. 
Before docking of the inhibitors was conducted, studies using the natural substrate ADP 
was done to refine the docking parameters. A Triangle Matcher placement method180 with 
London dG scoring function was applied with a maximum of 30 poses returned. The 
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structures generated by the placement method was further refined by either rigid receptor 
or induced fit with GBVI/WSA dG as the final scoring function, and the final output was 5 
poses. Both the rigid receptor and the induced fit refinement methods gave similar final 
poses, and for simplicity considerations, rigid receptor was used in the remaining docking 
studies. The final docking scores for the 5 output poses ranged between -11.72 to -11.31, 
and RMSD between the docked poses from the original ligand ranged between 1.07 to 2.12 
Å (Table 9). All five docked poses process similar interactions with the enzyme as observed 
in the crystal structure with ADP (Figure 25). Thus, these docking parameters were utilized 
in the exploration of binding models of the pyrido[2,3-d]pyrimidines. 
Table 9. The docking scores and RMSD values of the 5 output poses of ADP. The ranking 
was determined by the scoring function. 
# S RMSD (Å) 
1 -11.7250 1.0668 
2 -11.6590 1.9729 
3 -11.5331 1.7365 
4 -11.4915 1.0982 
5 -11.3173 2.1226 
1  
2  
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3  4  
5  
 
Figure 25. 2-D illustration of the 5 docked ADP poses interacting with the ATP-binding site 
of PurKAsp (PDB: 3K5I). Red: original ADP from X-ray structure. Green: docked ADP. 
To examine the binding of ligands, the parent inhibitor 11 was docked into the ATP-site 
of PurKAsp according to the method described above. The crystal structure of 11 came from 
it complexed with BC (PDB: 2V58). The 3D conformation of the ligand went through the 
conformation-check in MOE with no changes. The final scores for the 5 output poses ranged 
between -3.86 to -2.08, and RMSD between the docked 11 from the original ligand ranged 
between 0.92 to 2.07 Å (Table 10). All five docked poses differ from each other with the 
fourth pose (ranked by score) most resembling the binding model built from the structural 
alignment (Figure 26). 
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Table 10. The docking scores and RMSD values of the 5 output poses of inhibitor 11. The 
ranking was determined by the scoring function. 
# S RMSD (Å) 
1 -3.8590 1.6131 
2 -3.5136 1.6142 
3 -3.3461 2.0675 
4 -2.7844 0.9206 
5 -2.0818 1.3119 
1  2  
3  4  
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Figure 26. 2-D illustration of the 5 docked 11 poses interacting with the ATP-binding site of 
PurKAsp (PDB: 3K5I). Red: binding orientation from structural alignment. Green: docked 
pose. The enzyme was positioned to catch maximum interactions with the docked poses 
instead of the one from structural alignment. 
The SAR generated by 1,6-naphthyridine and 1,8-naphthyridine was used to evaluate 
the likelihood of the docked poses. The SAR of these two groups of compounds was 
weighed more heavily than the C-6 and N-7 derivatives because they are direct changes of 
the pyrido[2,3-d]pyrimidine core scaffolds while others are changes on side chains. Based 
on the SAR of 1,6-naphthyridine and 1,8-naphthyridine, N-1 and N-3 should form critical 
interactions with PurKAsp with the N-3 interaction being indispensable. Among the five 
docked poses, poses 3, 4, and 5 displayed the importance of N-1; and pose 1 and 5 
indicated that N-3 is significant. Given the fact that pose 4 is similar to the orientation 
generated by the structural alignment, we believe that docking pose 4 and 5 explains the 
SAR the best and should be given more consideration in future studies.  
Finally, all the C-6 and N-7 non-urea derivatives were docked into the ATP-site of 
PurKAsp using the same parameters. The crystal structure of 11 from it complexed with BC 
(PDB: 2V58) formed the basis of all the derivative conformation, and changes in the side 
chains were manually built into 11. The 3D conformations and charges of the ligands 
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manual input were then calculated and corrected by MOE’s Conformation Import. This 
function returns the lowest energy conformation of each derivative by decomposing each 
ligand into constituent overlapping fragments, performing stochastic conformational search 
on each fragment, and then assembling the fragments into unique conformers. Five docked 
poses were returned for each derivative. All the poses were further analyzed by the Protein 
Ligand Interaction Fingerprints (PLIF) tool in MOE. The PLIF is a method for summarizing 
the interactions between ligands and proteins using a fingerprint scheme180.  
 
Figure 27. Population display of the PLIF generated by all the docking poses of the C-6 
and N-7 non-urea derivatives. 
Figure 27 is a population display of the generated fingerprint. The columns for each 
residue represents the number of potential modes of interaction between this residue and 
the ligands. If there is more than one column for a residue, there is more than one pose that 
interacts with that residue. When we examine the residues interacting with the pyrido[2,3-
d]pyrimidine core scaffold, the four residues in the adenine binding pocket are Lys146, 
Glu181, Lys182, and Ala184. Among these four residues, each possess at least two poses, 
suggesting there are two dominant poses for the pyrido[2,3-d]pyrimidine core in all 
derivatives. A close examination revealed that these two dominant poses were represented 
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by the pose 4 and 5 in Figure 26, suggesting that the binding orientations generated by 
unbiased docking studies matched with that derived by SAR analysis. 
Since pose 4 is the same as that generated by the structural alignment to BC, detailed 
examination of this model was given in were given in section 2.7.1. Pose 5 was examined 
in the original PurKAsp structure. Rather than binding in the adenine-site, the pyrido[2,3-
d]pyrimidine core sat in the ribose-phosphate site of the ATP-binding site in pose 5, and the 
6-phenyl occupied the adenine binding site (Figure 28). Compared with the orientation 
generated by structural alignment, pose 5 was able to predict that the 3’, 5’-OH substituted 
6-phenyl and 3-(dimethylamino) propyl substituted 7-amino could form more interactions 
with PurKAsp (Figure 29), hence increasing activity. Pose 5 has its limitations as well. For 
example, this pose fails to predict the activity gain by small hydrophobic groups at 7-N. 
 
Figure 28. 2-D illustration of the docking pose 5 of pyrido[2,3-d]pyrimidine overlapping 
with ADP in the ATP-site of PurKAsp. Interactions with inhibitors were shown in green, 
while interactions with ADP were shown in red. 
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Figure 29. 2-D illustration of the docking pose 5 of 54 in PurKAsp. 
The docking studies remove the assumption that pyrido[2,3-d]pyrimidine binds the ATP-
site of PurKAsp in the same orientation as it binds BC. However, with no direct structural 
information, the possibilities for different derivatives possessing various orientations still 
hold. We should keep this in mind when using computational models to design future 
modifications.  
In summary, structural alignments and docking were used to generate potential binding 
orientations of pyrido[2,3-d]pyrimidine in the ATP-site of PurKAsp. The two most likely poses 
were identified with the heterocycle core sitting in the adenine site and ribose phosphate 
site, respectively. Both poses provide valid explanations for the SAR of changes on the 
heterocycle core. The second pose in which the pyrido[2,3-d]pyrimidine occupies the 
ribose-phosphate site is partially explained by the observed side chain SAR. Both poses 
should be given equal considerations when designing new pyridopyrimidine analogs.  
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CHAPTER 3 CONCLUSIONS 
Taking inspiration from the nanomolar inhibitors described against BC, we tested four 
different known scaffolds against PurK from two different microbial species. Only one 
compound, 1, containing a pyrido[2,3-d]pyrimidine core, weakly inhibits PurKAsp with an IC50 
of 167 μM, however this compound is inactive against PurKE. coli. Kinetic assays confirmed 
that 1 is an ATP-competitive inhibitor. With the guidance of computational modeling, we 
examined analogs of this lead agent with substituents in the ribose and triphosphate binding 
sites within the ATP-site. The ribose position modification, compound 14, has an IC50 of 14 
µM, a 12-fold increase in activity. Additional studies revealed a compound (34), with 
modification in the phosphate binding site with an IC50 of 24 µM. Combining these two 
substitutions gave compound 56 with an IC50 of 1.7 µM, a 100-fold improvement in potency 
from the lead agent. This compound is the most potent ATP-binding site inhibitor against 
PurKAsp described to date. The compounds reported here will serve as starting point to 
develop anti-fungal agents targeting the de novo purine biosynthesis pathway. 
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CHAPTER 4 FUTURE DIRECTIONS 
4.1 General future directions 
No antimicrobial studies were conducted for these compounds in our study. Considering 
pyrido[2,3-d]pyrimidines inhibited PurK from A. Clavatus better than that from E. coli, an 
antifungal study is warranted. However, the compounds described here still resemble 
inhibitors of BC and thus, further studies are needed to determine the BC activity of these 
agents.  Even if BC activity is limited, any potential antifungal activity must still be validated 
as the result of inhibiting PurK instead of BC. This could be accomplished by the use of CO2 
rescue studies182 which has been shown to be a selective rescue for PurK inactivity. For the 
long-term goal of antimicrobial drug development, a dual target inhibitor against both PurK 
and BC could be an interesting approach since this could reduce the chance of resistance 
development.  
To improve specificity and potency, continued structural modifications to obtain more 
potent compounds is a necessary. In the current study, computational models were used to 
suggest structural modifications. Although improved compounds were obtained, our models 
are hypothetical at best and are not based upon experimental evidence. To obtain direct 
binding information, X-ray analysis of protein:ligand complexes are needed. Fortunately, 
PurK has been crystallized121, 139, although no structure of an inhibitor:PurK complex has 
been described in the literature.  
4.2 Apply covalent inhibitor strategy to increase target specificity and selectivity 
Other approaches to increase activity could also be explored, including the use of 
covalent strategies. Traditionally, covalent inhibitors were often associated with a lack of 
target specificity and increased off-target and side effects183. However, the recent 
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successes with quiescent affinity labels used in protease184 and kinase inhibitors185 have 
reinvigorated interest in covalent inhibitors among many drug discovery researchers186-187.  
Affinity labels are molecules that have a chemically reactive functional group and will 
undergo chemical reaction to form a covalent bond with another molecule that processes a 
complementary group188. A popular example of an affinity label used as drugs is omeprazole. 
Omeprazole is converted to a more reactive sulphenamide under the acidic environment in 
the stomach. The sulphenamide reacts with a cysteine residue of the gastric H+/K+ ATPase 
to inhibit the enzyme activity and therefore is used to treat acid reflux disease188. Other 
examples of quiescent affinity labels in medical uses include aspirin and penicillin, and they 
both labels a serine residue in their target proteins.  
More recent successes for covalent inhibitors as drugs are the applications in the 
protease189-190 and kinase191 inhibitors. Added Michael acceptors onto the original non-
covalent inhibitors have led to agents that target cysteine residues in their target proteins 
rendering the protein inactive. Examples of these inhibitors are shown in Figure 30. 
 
Figure 30. Examples of covalent inhibitors. The Rhinovirus 3C protease inhibitor189-190 (a) 
and the epidermal growth factor receptors (EGRF) protein kinase inhibitor191 (b). The 
boxes indicate the Michael acceptor. 
Inspired by these results, we were interested to see if we could apply the covalent 
inhibitor strategy by adding a covalent warhead to our reversible PurK inhibitor pyrido[2,3-
d]pyrimidines. We will discuss our preliminary results in the following sections.  
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4.2.1 Using the cysteine modifier to probe cysteine functions in PurKAsp 
A close examination of the ATP-binding site of PurKAsp revealed that Cys266 has the 
potential to be targeted by quiescent affinity labels. Cys266 is in a β-sheet of the C1-domain 
of PurKAsp, and it is involved in the binding of the ribose phosphate part of the ATP (Figure 
31). Cys266 is about 40% conserved and involved in the binding of ATP in the ATP-grasp 
enzymes. Other than cysteine, a more common residue at this location is asparagine. 
Among the PurKs from different species, cysteine is conserved within all species of 
Aspergillus, Histoplasma capsulatum, Paracoccidioides brasiliensis, and 
Pseudogymnoascus. Asparagine is found from E. coli, S. aureus, Candida, and 
Cryptococcus. This divergence would increase the selectivity of the potential covalent 
inhibitors targeting PurK. 
 
Figure 31. Interaction of Cys266 with ADP in PurKAsp (pdb: 3K5I). 
A key question is whether Cys266 is reactive and thus could be targeted by covalent 
inhibitors. Given this question, we conducted studies aimed at examining whether N-methyl 
maleimide, a known cysteine reactive probe, would inhibit PurKasp by modifying Cys266.  
4.2.2 Probe the cysteine function using N-methyl maleimide 
The effect of N-methyl maleimide on PurK was measured by the PK/LDH coupled assay. 
Various concentrations of N-methyl maleimide were incubated with PurK from different 
organisms. Different effects of N-methyl maleimide were observed against PurKAsp and 
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PurKE. coli. For PurKAsp, activity was inhibited, and the progress curves showed a time-
dependent curvature. For PurKE. coli, N-methyl maleimide appeared to have no effect (Figure 
32). To further confirm that N-methyl maleimide directly inhibits PurKAsp in a time dependent 
fashion, N-methyl maleimide was pre-incubated with PurKAsp, and after 20 min, 93.5% of 
the enzymatic activity was lost. The curvature observed from N-methyl maleimide inhibiting 
PurKAsp could result from several factors including N-methyl maleimide reacting with the 
enzyme or reagents in the system, or the induction of conformational changes of the 
enzyme. Using the negative result from PurKE. coli, we can rule out the possibilities that N-
methyl maleimide reacts with reagents in the assay.  
  
Figure 32. PK/LDH coupled PurK reaction was initiated with PurK at time 0 and the 
conversion of NADH to NAD+ was measured at 340 nm. 
4.2.3 N-FITC maleimide binds PurKAsp and PurKE. coli covalently 
Based on the reactive nature of maleimide with the thiol of cysteines, it is logical to 
believe that N-methyl maleimide inhibits PurK by covalent modification. To confirm this, N-
FITC maleimide was incubated with PurKAsp and PurKE. coli at room temperature for 30 min. 
Excess N-FITC maleimide was removed by spin columns with 10K molecular weight cutoff. 
The enzymes were examined by reducing SDS-PAGE and fluorescent bands of both 
PurKAsp and PurKE. coli (Figure 33) were observed indicating that N-FITC maleimide modified 
both enzymes covalently.  
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Figure 33. FITC-maleimide covalently labeled both PurKAsp (45 kDa) and PurKE. Coli (40 kDa). 
1. PurKAsp + FITC-maleimide; 2. PurKAsp + DMSO; 3. PurKE. Coli + FITC-maleimide; 4. PurKE. 
Coli + DMSO. 
4.2.4 ATP protected PurKAsp from the time-dependent inhibition of N-methyl 
maleimide  
The fact that FITC-malemide also binds to PurKE. coli indicates that there are multiple 
cysteines that can be modified by the malemide reagents. Thus, it is unclear whether the 
inhibition of PurKAsp is due to inhibition of Cys266. To investigate the cause of the time-
dependent inhibition of PurKAsp, kinetic studies were carried out to see if ATP could protect 
PurKAsp from the inhibition of N-methyl maleimide. If the modification of PurKAsp by N-methyl 
maleimide could be prevented by the binding of ATP, increasing the ATP concentration 
should result in a decrease in the observed rate of inactivation (kobs). The PK/LDH assay 
was used to monitor the progress curve of PurKAsp with a fixed 100 µM concentration of N-
methylmaleimide while various concentrations of ATP were added. The resulting curves 
were fitted using Equation 1 to determine kobs for each experiment. A decrease kobs versus 
increase in ATP concentration indicates that ATP protects PurKAsp from N-methyl maleimide 
inhibition (Figure 34). This suggests that the inactivation of PurKAsp occurs because of a 
modification of a cysteine near the ATP-binding site. 
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Eq. 1 
 
 
Figure 34. PK/LDH coupled PurK reaction was initiated with PurK at time 0, and the 
conversion of NADH to NAD+ was measured at 340 nm. A fixed concentration of 100 µM 
N-methylmaleimide was presented in all reactions with increased concentrations of ATP 
as shown in the left. The progression curves were fitted to equation 1 to generate kobs. 
The secondary plot of kobs vs. [ATP]/Km (Km[ATP] = 60 µM142) was shown to the right and 
demonstrates a clear decrease in rate as the ATP concentration increases. 
4.2.5 The time-dependent inhibition of N-methyl maleimide against PurKAsp is not due 
to the modification of Cys266, but Cys216 
To further narrow the cause of the time-dependent inhibition, two mutant proteins 
C266S and C266A were made. We anticipated that both proteins would be active yet would 
not display inhibition in the presence of N-methyl maleimide. Both proteins indeed retained 
their catalytic activity. However, to our surprise, treatment with N-methyl maleimide resulted 
in time-dependent inhibition for both mutant proteins (Figure 35). This interesting, yet 
unexpected result, generated a few hypotheses. First, N-methyl maleimide does not 
covalently modify Cys266. Although Cys266 is an exposed residue, there is no direct 
evidence to indicate that it is modified. A second hypothesis is that N-methyl maleimide 
[𝑃] =
𝑣𝑖
𝑘𝑜𝑏𝑠
[1 − exp(−𝑘𝑜𝑏𝑠 ∗ 𝑡)] 
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covalently labels Cys266, yet this modification does not influence the enzymatic activity. To 
explore these hypotheses, we conducted additional experiments aimed at identifying the 
cysteine residue responsible for the inhibition of PurKAsp.  
A close examination of all of the cysteines in PurKAsp revealed that there are five 
cysteines (Figure 36). The remaining four cysteines are not conserved among ATP-grasp 
enzymes. Other than Cys266, Cys216 is the closest to the active sites. Therefore we made 
a mutant protein, C216S, and like the C266 mutants, this mutant also retained catalytic 
activity. To our great surprise, N-methyl maleimide did not inhibit the activity of the C216S 
mutant (Figure 35). It is challenging to form a plausible hypothesis as for how modification 
of Cys216 results in inhibition of the enzyme. The residue does not appear to interact with 
any substrate, although the sulfur atom is about 7.5 Å away from the free phosphate in the 
crystal structure (Figure 37). Cys216 is not a conserved residue and the analogous residue 
in PurKE. coli is Leu189.  
 These experiments showed that labeling Cys266 by N-methyl maleimide, if it does 
occur, did not render PurKAsp inactive. Our original idea to add a covalent warhead in 
pyrido[2,3-d]pyrimidine to target this residue requires modification.  
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Figure 35. PK/LDH coupled PurK reaction was initiated with PurK (WT or mutants) at 
time 0 and the conversion of NADH to NAD+ was measured at 340 nm. A fixed 
concentration of 100 µM N-methylmaleimide was presented in all runs. 
 
71 
 
 
 
Figure 36. PurKAsp (pdb: 3K5I).  5 cys, ADP, and AIR are shown in sticks. 
 
Figure 37. The relative position of Cys216 compared to the enzymatic substrates. (This 
is a preliminary figure just to show the position). 
  
Cys216 
His273 
ADP 
Pi 
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CHAPTER 5 METHODS AND MATERIALS 
5.1 Chemistry 
Reactions were run in anhydrous solvents purchased from Acros and used without 
further purification unless otherwise indicated. Argon was purchased from Airgas. Starting 
materials were purchased from Acros, Fisher, or Sigma and used without further purification 
unless otherwise indicated. Solvents used for work-ups and chromatography (methanol, 
acetone, dichloromethane, chloroform, ethyl acetate and hexanes) were purchased in bulk 
from Fisher.  
Microwave irradiation reactions were performed using a single-mode InitiatorTM 
Microwave Synthesizer from Biotage using standard Biotage vessels. Column 
chromatography was carried out on silica gel (Sorbtech). Reactions were monitored by 
analytical TLC (w/UV 254 nm) and visualized by UV (254 nm and 360 nm). 1H and 13C NMR 
spectra were recorded on Varian 600 MHz NMR without temperature regulation. Chemical 
shifts are given in ppm (δ) using tetramethylsilane (TMS) as an internal standard. Mass 
spectra were recorded by Micromass LCT Premier XE instrument (Waters) with ESI/TOF. 
 
Scheme 10. Synthesis of 7. Reagents and conditions: (a) NaH, EtOH, reflux, 24 h, 24%. 
Ethyl 2,7-diaminopyrido[2,3-d]pyrimidine-6-carboxylate (7). To a solution of sodium 
ethoxide prepared from NaH (4 mmol, 160 mg, 60% slurry in Hexanes) and ethanol (10 mL) 
was added ethyl cyanoacetate (10 mmol, 1.66 mL). The mixture was stirred under argon at 
room temperature for 15 min. To this, 1b192 (5 mmol, 680 mg) was added and the reaction 
was heated to reflux for 24 h and then cooled to room temperature. The resulting precipitate 
was collected by filtration and the solid washed with water, CH3CN and Et2O, sequentially. 
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Column chromatography (99/1 to 97.5/2.5 to 90/10 CH2Cl2/MeOH) gave 7 (276 mg, 1.18 
mmol, yield 24%) as a white solid. TLC (90/10 CH2Cl2/MeOH, Rf = 0.38). 1H NMR (600 MHz, 
DMSO-d6) δ 8.84 (1H, s, -ArH4), 8.56 (1H, s, -ArH5), 7.71 (2H, s, -NH2), 7.19 (2H, s, -NH2), 
4.31 (2H, q, J = 7.1 Hz, -CH2CH3), 1.34 (3H, t, J = 7.1 Hz, -CH2CH3). 13C NMR (150 MHz, 
DMSO-d6) δ 166.3 (COO), 165.2 (C2), 163.7 (C7), 162.7 (C6), 162.1 (C7a), 143.1 (C4), 
108.1 (C4a), 105.2 (C5), 61.2 (CH2), 14.6 (CH3). ES-MS [M+1] found 234.1, calculated for 
C10H12N5O2 234.2. 
 
Scheme 11. Synthesis of 6. Reagents and conditions: (a) 2 N NaOH, MeOH, reflux, 3 h, 
34%. 
2,7-Diaminopyrido[2,3-d]pyrimidine-6-carboxylic acid (6). A suspension of 7 (267 
mg, 1.1 mmol) in 2 N NaOH (10 mL) was heated at reflux for 3 h. The suspension became 
clear after heating for 15 min and remained clear. Water was removed in vacuo and the 
solid was recrystallization from water to give 6 as the sodium salt (pale yellow solid, 90 mg, 
0.4 mmol, yield 34%). TLC (90/10 CH2Cl2/MeOH, Rf = 0). 1H NMR (600 MHz, DMSO-d6) δ 
10.14 (1H, d, J = 6.1 Hz, -NH2), 8.57 (1H, s, -ArH4), 8.23 (1H, s, -ArH5), 6.94 (1H, d, J = 
6.1 Hz, -NH2), 6.53 (2H, s, -NH2). 13C NMR (150 MHz, CD3OD) δ 172.0 (COOH), 169.7 (C2), 
163.4 (C7), 163.1 (C8a), 162.0 (C4), 140.9 (C5), 112.7 (C6), 106.6 (C4a). ES-MS [M-1] 
found 204.1, calculated for C8H6N5O2 204.0. 
General method for cyclization (1, 8-13, 15-22, 62-66, 71)193. The reactions were run 
in 0.2 – 1 mmol scale. 2-Ethoxyethanol was dried over K2CO3, distilled and stored over 
molecular sieves.  To a solution of sodium 2-ethoxyethoxide (4 eq), prepared from NaH and 
2-ethoxyethanol, was added various acetonitriles (2 eq). The mixture was stirred under 
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argon at room temperature for 30 min to 3 h. To the reaction, 1b192 (8c for 1,6-
naphthyridines) (1 eq) was added and the reaction was heated at reflux for 4 h. The reaction 
was cooled to room temperature, poured into cold water and chilled at 4 °C overnight. The 
resulting precipitate was collected by filtration and sequentially washed with water, CH3CN 
and Et2O. The solids were dried in vacuo to give 1, 8-13, and 15-22, 71. Compound 1, 5, 9-
13, 15-17 was synthesized following a literature method161. Compound 19, 21, and 22 were 
made based on a patent194. Compound 20 was made based on a patent195. Naphthyridines 
62-66 were made based on the literature196-198. NMR analysis of the literature compounds 
agreed with the published values and thus are not listed below. 
2-Ethoxyethyl 2,7-diaminopyrido[2,3-d]pyrimidine-6-carboxylate (8). Brown solid 
(42%). TLC (90/10 CH2Cl2/MeOH, Rf = 0.42). 1H NMR δ 8.86 (1H, s, -ArH4), 8.54 (1H, s, -
ArH5), 7.69 (2H, s, -NH2), 7.20 (2H, s, -NH2), 4.38 (2H, d, J = 4.3 Hz, -COOCH2CH2), 3.70 
(2H, d, J = 4.7 Hz, -COOCH2CH2), 3.51 (2H, q, J = 7.0 Hz, -OCH2CH3), 1.13 (3H, t, J = 7.0 
Hz, -OCH2CH3). 13C NMR (150 MHz, DMSO-d6) δ 166.2 (COO), 163.2 (C2), 161.7 (C7), 
157.1 (C7a), 145.1 (C4), 135.2 (C5), 115.7 (C6), 109.1 (C4a), 68.2 (CH2CH2), 67.2 
(CH2CH3), 63.2 (CH2CH2), 14.6 (CH3). ES-MS [M+1] found 278.1, calculated for C12H16N5O3 
278.3. 
6-(Naphthalen-2-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (18). Yellow solid (yield 
69%). TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.54). 1H NMR (600 MHz, DMSO-d6) δ 8.70 
(1H, s, -ArH4), 8.05 – 7.95 (5H, m, -NapH), 7.77 (1H, s, -ArH5), 7.61 – 7.52 (4H, m, -NapH, 
-NH2), 6.74 (2H, s, -NH2). 13C NMR (150 MHz, DMSO-d6) δ 163.9 (C2), 161.5 (C7), 160.9 
(C8a), 160.8 (C4), 137.4 (C5), 135.0 (C2’), 133.7 (C4a’), 132.8 (C8a’), 128.9 (C5’), 128.5 
(C8’), 128.0 (C3’), 128.0 (C4’), 127.3 (C7’), 126.8 (C6’), 126.7 (C1’), 121.0 (C6), 109.2 (C4a). 
ES-MS [M+1] 288.0, calculated for C17H14N5 288.1. 
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6-(1-Trityl-1H-imidazol-4-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (71). The solid and 
the CH3CN fraction were combined and concentrate to dryness in vacuo. Column 
chromatography (0 to 4% MeOH in DCM to 94.5/5/0.5 to 92/7.5/0.5 CH2Cl2/MeOH/NH4OH) 
gave 71 (yield 45%) as a dark brown solid. TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 
0.17). 1H NMR (600 MHz, CDCl3) δ 8.57 (1H, s, -ArH4), 7.71 (1H, s, -ArH5), 7.52 (1H, d, J 
= 1.3 Hz, -imidH2’), 7.42 – 7.35 (10H, m, -TrtH), 7.22 (1H, d, J = 1.4 Hz, -imidH5’), 7.21 – 
7.17 (7H, m, -TrtH, -NH2), 5.12 (2H, s, -NH2). 13C NMR (150 MHz, CDCl3) δ 162.7 (C2), 
161.2 (C7), 160.0 (C8a), 159.7 (C4), 141.9 (Ph), 138.1 (C4’), 138.0 (C2’), 131.8 (C5), 129.7 
(Ph), 128.3 (Ph), 128.2 (Ph), 118.5 (C5’), 113.1 (C6), 109.3 (C4a), 75.9 (C). ES-MS [M+1] 
470.0, calculated for C29H24N7 470.2. 
 
Scheme 12. Synthesis of 14. Reagents and conditions: (a) BBr3, CH2Cl2, 0 ºC to r.t., 24 
h, 43%. 
5-(2,7-Diaminopyrido[2,3-d]pyrimidin-6-yl)benzene-1,3-diol (14). A solution of 15192 
(148 mg, 0.5 mmol) in anhydrous CH2Cl2 (3 mL) was cooled to 4 ºC in an ice bath. A solution 
of BBr3 in CH2Cl2 (5 mmol, 1M, 5 mL) was added dropwise to the reaction and the reaction 
was stirred overnight. Water (2 mL) was added to quench the reaction and the precipitate 
was collected by filtration and dried in vacuo. Column chromatography (78/20/2 
CH2Cl2/MeOH/NH4OH) gave 14 (58 mg, 0.21 mmol, yield 43%) as a dark brown solid. TLC 
(4/1 EtOAc/MeOH, Rf = 0.16). 1H NMR (600 MHz, DMSO-d6) δ 9.43 (2H, s, 2×-OH), 8.64 
(1H, s, -ArH4), 7.58 (1H, s, -ArH5), 6.64 (2H, s, -NH2), 6.26 (2H, d, J = 2.1 Hz, -PhH2’, 6’), 
6.24 (1H, t, J = 2.1 Hz, -PhH4’). 13C NMR (150 MHz, DMSO-d6) δ 162.4 (C2), 162.1 (C4), 
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160.0 (C7), 159.4 (C3’), 156.5 (C8a), 137.9 (C1’), 137.2 (C5), 121.9 (C6), 108.0 (C4a), 
107.2 (C2’), 103.0 (C4’). ES-MS [M+1] found 270.1, calculated for C13H12N5O2 270.1. 
 
Scheme 13. Synthesis of 23. Reagents and conditions: (a) TFA, r.t., 1 h, 83%. 
6-(1H-Imidazol-4-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (23). A suspension of 71 
(47 mg, 0.1 mmol) in TFA (1 mL) was stirred in a sealed vial at room temperature for 1 h. 
The reaction was concentrated to dryness in vacuo and the residue purified by column 
chromatography (94.5/5/0.5 to 78/20/2 CH2Cl2/MeOH/NH4OH) to give 23 (19 mg, 0.08 mmol, 
yield 83%) as a yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.07). 1H NMR (600 
MHz, DMSO-d6) δ 12.46 (1H, s, -imidNH), 8.57 (1H, s, -ArH4), 8.08 (1H, s, -ArH5), 7.82 
(1H, d, J = 1.2 Hz, -imidH2’), 7.69 (1H, d, J = 1.3 Hz, -imidH5’), 6.65 (2H, s, -NH2). 13C NMR 
(150 MHz, CDCl3) δ 163.7 (C2), 158.2 (C7), 167.0 (C8a), 150.7 (C4), 139.1 (C4’), 138.8 
(C2’), 135.8 (C5), 118.5 (C5’), 118.1 (C6), 109.3 (C4a). ES-MS [M+1] found 228.1, 
calculated for C13H12N5O2 228.1. 
 
Scheme 14. Synthesis of pyrido[2,3-d]pyrimidines with various substitutions at the 7-NH2 
position. Reagents and conditions: (a) neat amine, reflux, 6-12 h, 34-68 %. 
General method for N7-substitution (27-29, 31-35). A suspension of 1e194 (51 mg, 0.2 
mmol) in various neat amines (1-3 mL, 60-150 eq) was refluxed for 6 to 12 h, and the excess 
amines were removed in vacuo. Column chromatography of the residue gave 27-29, 31-35 
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in moderate yields. Compound 27 was made following a patent method194. NMR analysis 
of 27 was consistent with the literature analysis.  
N7-Cyclopentyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (28). Column 
chromatography (1 to 3% MeOH/CH2Cl2 to 94/5/1 CH2Cl2/MeOH/NH4OH) gave 28 as a 
yellow solid (30 mg, yield 50%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.57). 1H NMR 
(600 MHz, CDCl3) δ 8.59 (1H, s, -ArH4), 7.53 – 7.47 (2H, m, -Ph), 7.47 – 7.41 (2H, m, -Ph), 
7.43 – 7.37 (2H, m, -ArH5, -Ph), 5.53 – 5.41 (2H, m, -NH2), 5.22 (1H, d, J = 7.5 Hz, -NH), 
4.78 – 4.69 (1H, m, -CH), 2.18 – 2.09 (2H, m, -CH2), 1.66 – 1.58 (4H, m, -CH2CH2-), 1.39 – 
1.29 (2H, m, -CH2). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 161.3 (C7), 159.8 (C4), 159.4 
(C8a), 136.5 (C1’), 135.0 (C5), 129.4 (C3’), 128.9 (C2’), 128.4 (C4’), 123.1 (C6), 109.2 
(C4a), 52.6 (CH), 33.2 (CH2), 23.6 (CH2). ES-MS [M+1] 306.2, calculated for C18H20N5 306.2. 
N7-Cyclopropyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (29). Column 
chromatography (1 to 3% MeOH/CH2Cl2) gave 29 as a yellow solid (22 mg, yield 40%). TLC 
(94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.49). 1H NMR (600 MHz, CDCl3) δ 8.64 (1H, s, -
ArH4), 7.52 – 7.45 (3H, m, -ArH5, -Ph2’), 7.46 – 7.40 (1H, m, -Ph4’), 7.39 – 7.34 (2H, m, -
Ph3’), 5.39 – 5.28 (3H, m, -NH, -NH2), 3.10 (1H, tq, J = 3.7, 7.3 Hz, -CH), 0.94 – 0.85 (2H, 
m, -CH2), 0.52 – 0.45 (2H, m, -CH2). 13C NMR (600 MHz, CDCl3) δ 163.0 (C2), 161.2 (C8a), 
160.9 (C7), 160.1 (C4), 136.3 (C1’), 135.1 (C5), 129.4 (C3’), 128.9 (C2’), 128.5 (C4’), 123.0 
(C6), 109.6 (C4a), 24.7 (CH), 7.5 (CH2). ES-MS [M+1] 278.0, calculated for C16H16N5 278.1. 
N7,N7-Diethyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (31). Column 
chromatography (1 to 3% MeOH/CH2Cl2 to 94/5/1 CH2Cl2/MeOH/NH4OH) gave 31 as a 
yellow solid (36 mg, yield 68%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.43). 1H NMR 
(600 MHz, CDCl3) δ 8.65 (1H, s, -ArH4), 7.52 (1H, s, -ArH5), 7.45 – 7.39 (4H, m, -Ph2’, 3’), 
7.38 – 7.30 (1H, m, -Ph4’), 5.55 (2H, s, -NH2), 3.39 (4H, q, J = 7.0 Hz, 2×-CH2CH3), 1.04 
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(6H, t, J = 7.1 Hz, 2×-CH2CH3). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 162.5 (C7), 160.2 
(C4), 159.7 (C8a), 140.5 (C1’), 138.8 (C5), 128.8 (C3’), 127.6 (C2’), 127.3 (C4’), 124.7 (C6), 
109.7 (C4a), 44.2 (CH2), 13.0 (CH3). ES-MS [M+1] 266.1, calculated for C17H20N5 266.1. 
6-Phenyl-N7-(prop-2-yn-1-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (32). Column 
chromatography (1 to 3% MeOH/CH2Cl2) gave 32 as a yellow solid (36 mg, yield 67%). TLC 
(94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.25). 1H NMR (600 MHz, CDCl3) δ 8.66 (1H, s, -
ArH4), 7.55 – 7.48 (3H, m, -ArH5, -Ph), 7.48 – 7.40 (3H, m, -Ph), 5.54 (2H, s, -NH2), 5.38 
(1H, t, J = 5.1 Hz, -NH), 4.44 (2H, dd, J = 2.6, 5.1 Hz, CH2), 2.22 (1H, t, J = 2.5 Hz, -C≡CH). 
13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 160.8 (C8a), 160.4 (C4), 158.8 (C7), 135.9 (C1’), 
135.6 (C5), 129.5 (C3’), 129.0 (C2’), 128.6 (C4’), 122.9 (C6), 109.5 (C4a), 80.1 (C≡CH), 
71.6 (C≡CH), 31.4 (CH2). ES-MS [M+1] 276.3, calculated for C16H14N5 276.1. 
N7-Methyl-6-phenyl-N7-(prop-2-yn-1-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (33). 
Column chromatography (1st 1 to 3% MeOH/CH2Cl2; 2nd 67 to 100% EtOAc/hexane) gave 
33 as a yellow solid (20 mg, yield 34%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.41). 
1H NMR (600 MHz, CDCl3) δ 8.74 (1H, s, -ArH4), 7.66 (1H, s, -ArH5), 7.49 – 7.42 (4H, m, -
Ph2’, 3’), 7.41 – 7.33 (1H, m, -Ph4’), 5.52 (2H, s, -NH2), 4.21 (2H, d, J = 2.4 Hz, CH2), 2.88 
(3H, s, -CH3), 2.18 (1H, t, J = 2.5 Hz, CH). 13C NMR (600 MHz, CDCl3) δ 163.2 (C2), 162.6 
(C7), 160.8 (C4), 159.3 (C8a), 139.6 (C1’), 139.2 (C5), 129.0 (C3’), 127.7 (C2’), 127.5 (C4’), 
124.1 (C6), 110.2 (C4a), 79.4 (-C≡CH), 72.2 (-C≡CH), 41.7 (CH2), 38.9 (CH3). ES-MS [M+1] 
290.2, calculated for C17H16N5 290.1. 
N7-(3-(Dimethylamino)propyl)-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (34). 
Column chromatography (3% MeOH/CH2Cl2 to 94/5/1 to 89/10/1/ CH2Cl2/MeOH/NH4OH) 
gave 34 as a yellow solid (28 mg, yield 43%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 
0.18). 1H NMR (600 MHz, CDCl3) δ 8.55 (1H, s, -ArH4), 7.55 (1H, t, J = 4.4 Hz, -NH), 7.49 
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– 7.43 (2H, m, -Ph), 7.46 – 7.35 (4H, m, -ArH5, -Ph), 5.52 (2H, s, -NH2), 3.75 – 3.69 (2H, 
m, -NHCH2CH2CH2), 2.32 (2H, d, J = 5.8 Hz, -NHCH2CH2CH2), 1.86 (6H, s, -N(CH3)2), 1.68 
(2H, p, J = 5.9 Hz, -NHCH2CH2CH2). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 161.4 (C8a) 
160.2 (C7), 159.5 (C4), 136.9 (C1’), 134.7 (C5), 129.2 (C3’), 128.9 (C2’), 127.9 (C4’), 123.8 
(C6), 109.0 (C4a), 59.2 (-NHCH2CH2CH2), 44.9 (-N(CH3)2), 42.6 (-NHCH2CH2CH2), 24.8 (-
NHCH2CH2CH2). ES-MS [M+1] 323.2, calculated for C18H23N6 323.2. 
N7-(2-(dimethylamino)ethyl)-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (35). 
Column chromatography (1st 1 to 3% MeOH/CH2Cl2 to 94/5/1 to 89/10/1 
CH2Cl2/MeOH/NH4OH; 2nd 94/5/1 CH2Cl2/MeOH/NH4OH) gave 35 as a yellow solid (30 mg, 
yield 48%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.13). 1H NMR (600 MHz, CDCl3) 
δ 8.59 (1H, s, -ArH4), 7.51 – 7.45 (3H, m, -ArH5, -Ph), 7.45 – 7.39 (3H, m, -Ph), 6.08 (1H, 
t, J = 4.8 Hz, -NH), 5.42 (2H, s, -NH2), 3.67 (2H, td, J = 4.8, 6.0 Hz, -NHCH2CH2), 2.49 (2H, 
t, J = 6.0 Hz, -NHCH2CH2), 2.17 (6H, s, -N(CH3)2). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 
161.3 (C7), 159.8 (C4), 159.7 (C8a), 136.4 (C1’), 135.0 (C5), 129.2 (C3’), 128.9 (C2’), 128.3 
(C4’), 123.4 (C6), 109.3 (C4a), 57.4 (-NHCH2CH2), 45.0 (-N(CH3)2), 38.9 (-NHCH2CH2). ES-
MS [M+1] 309.1, calculated for C17H21N6 309.2. 
 
Scheme 15. Synthesis of 24 and 25. Reagents and conditions: (a) 2,4-
dimethoxybenzylamine, Cs2CO3, dioxane, reflux, 4 h, 40%; (b) BBr3, CH2Cl2, 0 ºC to r.t., 24 
h, 20%. 
N7-(2,4-Dimethoxybenzyl)-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (24). A 
suspension of 2,4-dimethoxybenzylamine (33 µL, 0.22 mmol) and Cs2CO3 (215 mg, 0.66 
mmol) in dioxane (3 mL) was refluxed for 45 min before adding 1e (51 mg, 0.2 mmol). The 
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reaction was continued to reflux for 10 h. The reaction solids were removed by filtration and 
the filtrate was dried in vacuo. Column chromatography of the filtrate (0 to 5% MeOH in 
CH2Cl2 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 24 (31 mg, yield 40%) as a brown solid. TLC 
(4/1 EtOAc/MeOH, Rf = 0.66). 1H NMR (600 MHz, CDCl3) δ 8.58 (1H, s, -ArH4), 7.48 – 7.37 
(6H, m, -ArH5, -Ph), 7.27 (1H, d, J = 8.9 Hz, -Ph), 6.44 – 6.39 (2H, m, -Ph), 6.01 (1H, t, J = 
5.5 Hz, -NH), 5.47 (2H, s, -NH2), 4.77 (2H, d, J = 5.5 Hz, -CH2), 3.77 (3H, s, -CH3), 3.67 
(3H, s, -CH3). 13C NMR (150 MHz, CDCl3) δ 163.0 (C2), 161.2 (C7), 160.4 (C4’’), 159.8 (C4), 
159.5 (C8a), 158.7 (C2’’), 136.5 (C1’), 135.0 (C5), 130.6 (C6’’), 129.2 (C3’), 129.0 (C2’), 
128.3 (C4’), 123.4 (C1’’), 118.7 (C6), 109.3 (C4a), 103.8 (C5’’), 98.6 (C3’’), 55.4 (CH3), 55.0 
(CH3), 41.4 (CH2). ES-MS [M+1] found 388.2, calculated for C22H22N5O2 388.2. 
4-(((2-Amino-6-phenylpyrido[2,3-d]pyrimidin-7-yl)amino)methyl)benzene-1,3-diol 
(25). The synthesis of compound 25 followed the same procedure as for compound 14. 
Column chromatography (0 to 3% MeOH in CH2Cl2 to 94.5/5/0.5 CH2Cl2/MeOH/NH4OH) 
gave 25 (yield 20%) as a brown solid. TLC (4/1 EtOAc/MeOH, Rf = 0.23). 1H NMR (600 
MHz, DMSO-d6) δ 11.06 (1H, d, J = 6.3 Hz, -OH), 9.13 (1H, s, -OH), 8.67 (1H, s, -ArH4), 
7.62 (1H, s, -ArH5), 7.54 – 7.39 (5H, m, -Ph), 7.20 (1H, t, J = 6.1 Hz, -NH), 6.99 (1H, d, J = 
8.2 Hz, -Ph5’), 6.86 (2H, s, -NH2), 6.19 (1H, d, J = 2.5 Hz, -Ph4’), 6.15 (1H, dd, J = 2.4, 8.1 
Hz, -Ph2’), 4.35 (2H, s, -NH2). 13C NMR (150 MHz, DMSO-d6) δ 163.2 (C2), 161.2 (C7), 
158.5 (C8a), 158.4 (C4’’), 155.4 (C2’’), 150.8 (C4), 136.4 (C1’), 135.0 (C5), 130.6 (C6’’), 
129.2 (C3’), 129.0 (C2’), 128.3 (C4’), 115.4 (C1’’), 110.8 (C6), 109.3 (C4a), 108.8 (C5’’), 
103.4 (C3’’), 41.4 (CH2).  ES-MS [M+1] found 359.9, calculated for C20H18N5O2 360.1. 
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Scheme 16. Synthesis of 26. Reagents and conditions: (a) piperidin-4-ol, KOtBu, dioxane, 
reflux, 4 h, 29%. 
1-(2-Amino-6-phenylpyrido[2,3-d]pyrimidin-7-yl)piperidin-4-ol (26). A solution of 
piperidin-4-ol (21 mg, 0.2 mmol) and KOtBu (0.22 mmol, 25 mg) in dioxane (5 mL) was 
stirred under argon at room temperature for 1 h. To the reaction, 1e (51 mg, 0.2 mmol) was 
added and the reaction was heated to reflux for 4h. The resulting solids were removed by 
filtration and the solution was dried in vacuo. Column chromatography (1% MeOH in CH2Cl2 
to 94.5/5/0.5 CH2Cl2/MeOH/NH4OH) of the residue gave 26 as a yellow solid (19 mg, yield 
29%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.18).  1H NMR (600 MHz, DMSO-d6) δ 
8.80 (1H, s, -ArH4), 7.79 (1H, s, -ArH5), 7.54 (2H, dd, J = 1.4, 8.1 Hz, -Ph3’), 7.47 (2H, t, J 
= 7.7 Hz, -Ph2’), 7.36 (1H, t, J = 7.4 Hz, -Ph4’), 6.86 (1H, s, -NH2), 4.65 (1H, d, J = 4.1 Hz, 
-OH), 3.61 – 3.54 (3H, m, -CH, -piperH), 2.88 (2H, td, J = 2.8, 11.5 Hz, -piperH), 1.65 – 1.60 
(2H, m, -piperH), 1.34 – 1.25 (2H, m, -piperH). 13C NMR (150 MHz, CDCl3) δ 163.6 (C2), 
163.0 (C7), 160.6 (C4), 159.6 (C8a), 139.9 (C1’), 138.8 (C5), 129.1 (C3’), 127.6 (C4’), 127.2 
(C2’), 124.9 (C6), 110.4 (C4a), 67.6 (-CHOH), 46.1 (-NCH2CH2), 34.0 (-NCH2CH2). ES-MS 
[M+1] found 322.0, calculated for C18H20N5O 322.2. 
 
Scheme 17. Synthesis of 30. Reagents and conditions: (a) SOCl2, DMF, CH2Cl2, mw, 
70 °C, 1 h, 78%; (b) EtOH, reflux, 12 h, 57%. 
N'-(7-chloro-6-phenylpyrido[2,3-d]pyrimidin-2-yl)-N,N-dimethylformimidamide 
(1d)193. In a 20-mL microwave reaction vessel, a solution of 1c193 (952 mg, 4 mmol) in 
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anhydrous DMF (3 mL) and freshly distilled SOCl2 ( 15 mL) was irradiated at 70 °C for 1 h 
(absorbance: high). The reaction was transferred to a 250-mL round bottom flask and dried 
in vacuo. The residue was dissolved in ice water and the pH was adjusted to 10 using 6 N 
NaOH. After chilling at 4 °C overnight, the precipitate was collected by filtration, rinsed with 
cold water and dried in vacuo to give 1d (969 mg, yield 78%) as a pale yellow solid. TLC 
(9/1 EtOAc/MeOH, Rf = 0.26). 1H NMR (600 MHz, DMSO-d6) δ 9.45 (1H, s, -ArH4), 8.90 
(1H, s, -ArH5), 8.45 (1H, s, -N=CH-), 7.59 – 7.45 (5H, m, -Ph), 3.24 (3H, s, -NCH3), 3.14 
(3H, s, -NCH3). ES-MS [M+1] found 312.1, calculated for C16H10ClN5 312.1. 
7-Chloro-6-phenylpyrido[2,3-d]pyrimidin-2-amine (1e)193, N7,N7-dimethyl-6-
phenylpyrido[2,3-d]pyrimidine-2,7-diamine (30) (Method 1). A mixture of 1d (2 g, 6.4 
mmol) and ethanol (100 mL) was refluxed overnight. The solution was reduced to about 50 
mL in vacuo and chilled at 4 °C for 5 h. The precipitate was collected by filtration. Column 
chromatography (3/2 CH2Cl2/EtOAc) of the residue gave the major product 1e as the first 
fraction and by-product 30 as the second fraction. Compound 1e was obtained as a bright 
yellow solid (935 mg, yield 57%). TLC (4/1 hexane/EtOAc, Rf = 0.45). 1H NMR (600 MHz, 
DMSO-d6) δ 9.24 (1H, s, -ArH4), 8.29 (1H, s, -ArH5), 7.55 – 7.43 (7H, m, -Ph, -NH2). 13C 
NMR (150 MHz, DMSO-d6) δ 164.5 (C4), 164.2 (C2), 159.0 (C8a), 155.5 (C7), 140.5 (C5), 
137.4 (C6), 130.6 (C1’), 130.0 (C3’), 128.8 (C2’), 128.6 (C4’), 113.1 (C4a). ES-MS [M+1] 
found 257.1, calculated for C13H10ClN4 257.1. Compound 30 was obtained as a pale yellow 
solid (326 mg, yield 19%). TLC (4/1 hexane/EtOAc, Rf = 0.08). 1H NMR (600 MHz, DMSO-
d6) 8.77 (1H, s, -ArH4), 7.77 (1H, s, -ArH5), 7.49 – 7.40 (4H, m, -Ph), 7.38 – 7.32 (1H, m, -
Ph), 6.80 (2H, s, -NH2). 13C NMR (150 MHz, DMSO-d6) δ 163.1 (C2), 163.0 (C7), 160.4 
(C4), 159.6 (C8a), 140.3 (C1’), 138.8 (C5), 128.8 (C3’), 127.7 (C2’), 127.3 (C4’), 123.9 (C6), 
109.8 (C4a), 41.3 (NCH3). ES-MS [M+1] found 266.1, calculated for C15H16N5 266.1. 
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N7,N7-Dimethyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (30) (Method 2). In a 5-
mL microwave reaction vessel, 1e (51 mg, 0.2 mmol) was added to a dimethylamine/THF 
solution (2 M, 2 mL, 4 mmol). The mixture was irradiated at 70 °C for 2.5 h (absorption: 
poor) and the solvent was removed in vacuo. Column chromatography (94.5/5/0.5 to 
78/20/2 CH2Cl2/MeOH/NH4OH) gave 30 (51 mg, yield 97%) as a yellow solid. 
 
Scheme 18. Synthesis of 36. Reagents and conditions: (a) MeOH, DIPEA, reflux, 12 h, 
80%. 
7-Methoxy-6-phenylpyrido[2,3-d]pyrimidin-2-amine (36). A suspension of 1e194 (51 
mg, 0.2 mmol) and DIPEA (70 µL, 0.4 mmol) in MeOH (3 mL) was refluxed for 12 h, and 
then concentrated to dryness in vacuo. Column chromatography (94.5/5/0.5 to 78/20/2 
CH2Cl2/MeOH/NH4OH) gave 36 (40 mg, yield 80%) as a yellow solid. TLC (4/1 
hexane/EtOAc, Rf = 0.2).  1H NMR (600 MHz, CDCl3) δ 8.89 (1H, s, -ArH4), 7.86 (1H, s, -
ArH5), 7.60 – 7.53 (2H, m, -Ph2’), 7.49 – 7.43 (2H, m, -Ph3’), 7.43 – 7.37 (1H, m, -Ph1’), 
5.49 (2H, s, -NH2), 4.15 (3H, s, -OCH3). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 158.0 
(C7), 159.6 (C8a), 148.4 (C4), 138.8 (C5), 136.3 (C1’), 128.8 (C3’), 127.5 (C2’), 127.3 (C4’), 
125.9 (C6), 109.8 (C4a), 54.4 (OCH3). ES-MS [M+1] found 253.1, calculated for C14H13N4O 
253.1. 
General method for urea formation (38-50). To a solution of 1 (48 mg, 0.2 mmol) in 
DMF (5 mL) was added 60% NaH (10 mg, 0.24 mmol). The reaction mixture was stirred at 
room temperature for 1 h, followed by the addition of various isocyanates (0.24 mmol, 1.2 
eq). The reaction mixture stirred at room temperature overnight and the solvent was 
removed under high vacuum and the residue was directly purified by column 
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chromatography (94.5/5/0.5 to 78/20/2 CH2Cl2/MeOH/NH4OH) to give 38-50 in moderate 
yields.  Compound 38, 39, 43-46 was made following a patent method194. Compound 40-
42 was made following the literature153. Compound 47-50 was made following the 
literature169. NMR analysis of the literature compounds were in agreement with the literature 
values and are not reported here. 
2,6-Difluoro-5-iodonicotinaldehyde (7c)172. 7c was made from commercially available 
2,6-difluoronicotinaldehyde using a modified procedure172. A solution of 2,6-
difluoronicotinaldehyde (2.86 g, 20 mmol), triethyl orthoformate (5 mL, 30 mmol) and p-
toluenesulfonic acid (380 mg, 2 mmol) in ethanol (60 mL) was heated at reflux overnight. 
The solvent was removed and the residue was diluted with EtOAc and washed with sat. 
NaHCO3 and brine. The organic layer was dried over MgSO4 and concentrated in vacuo.  
Silica column chromatography (0 to 5% EtOAc in pet ether) gave the protected compound 
7a (3.6 g, yield 83%) as a clear, colorless oil. TLC (4/1 EtOAc/Hexanes, Rf = 0.68). This 
material was used in the next step. In a flame-dried 250 mL 3-neck round bottom flask, a 
solution of freshly distilled diisopropylamine (3.37 mL, 24 mmol) in anhydrous THF (8 mL) 
was cooled in a dry ice-acetone bath. A thermometer was inserted into the reaction to 
monitor temperature. After the mixture was cooled to under -60 °C, a solution of n-
butyllithium (1.5 M in hexanes) (14.4 mL, 21.6 mmol) was added dropwise through a 
dropping funnel. The speed of addition was controlled so that the temperature was always 
below -60 °C. The mixture was stirred at -60 °C for 5 min and warmed to room temperature 
and stirred for 10 min. The mixture was recooled to -70 °C in the dry ice-acetone bath and 
a solution of 7a (1.736 g, 8 mmol) in 8 mL THF was injected slowly to prevent the 
temperature rising above -60 °C. The mixture was stirred at -70 °C for 90 min. To this 
reaction, a solution of iodine (2.64g, 10.4 mmol) in 40 mL THF was added using a syringe 
85 
 
 
pump (20 mL/h) over a 2 h period. After the addition of iodine, the reaction was removed 
from the dry ice-acetone bath and the temperature slowly rose to room temperature. The 
reaction was treated with sat. NaHSO3 (40 mL) for 60 min before diluting with 250 mL EtOAc 
and washed with 1 N HCl (2×100 mL) and brine (150 mL). The organic phase was dried 
over MgSO4 and concentrated in vacuo to give an oil that slowly solidified affording 7b (2.65 
g, 7.7 mmol, yield 96%) as a white solid. TLC (4/1 EtOAc/Hexanes, Rf = 0.78). The final 
product was obtained as follows. A solution of 7b (1.11 g, 3.2 mmol) and HCl (1 N in water, 
12 mL, 12 mmol) in THF (12 mL) was added to a round-bottom flask and the flask was 
sealed by septum and parafilm. The reaction was incubated at room temperature for 4 days. 
The reaction was directly poured into a separation funnel and diluted with 50 mL EtOAc. 
The organic layer was washed with sat. NaHCO3 followed by brine. The organic layer was 
dried over MgSO4 and concentrated in vacuo. Silica column chromatography (0 to 5% 
EtOAc in Hexanes) gave 7c (0.84 g, yield 96%) as a white solid. TLC (4/1 EtOAc/Hexanes, 
Rf = 0.88). 1H NMR (600 MHz, CDCl3) δ 10.18 (1H, s, -CHO), 8.73 (1H, t, J = 8.1 Hz, -ArH). 
13C NMR (150 MHz, CDCl3) δ 183.4 (CHO), 163.7 (dd, J = 14.6, 10.2 Hz, C6), 162.0 (dd, J 
= 14.5, 3.9 Hz, C2), 152.5 (dd, J = 5.2, 2.5 Hz, C4), 117.6 (dd, J = 20.9, 5.8 Hz, C3), 71.3 
(dd, J = 41.3, 5.7 Hz, C5). ES-MS [M+1] found 269.7, calculated for C6H3F2INO 269.9. 
6-((3-(Dimethylamino)propyl)amino)-2-fluoro-5-iodonicotinaldehyde (7d)173. To a 
reaction under argon, a solution of 7c (716 mg, 2.67 mmol) in anhydrous DMSO (20 mL) 
was treated with 3-(dimethylamino)propylamine (352 µL, 2.79 mmol) and K2CO3 (735 mg, 
5.34 mmol) and stirred at room temperature for 2 h. The reaction mixture was poured into 
200 mL of water and chilled at 4 °C overnight. A pale-yellow precipitate was collected by 
filtration and the solid was washed with cold water. The solid was re-dissolved with 5 mL 
1:1 CH2Cl2 / MeOH, and the insoluble impurities were discarded. The organic solution was 
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concentrated and dried in vacuo to give 7d (733 mg, 78% yield) as a pale yellow solid. TLC 
(94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.15). 1H NMR (600 MHz, CDCl3) δ 9.88 (1H, s, -
CHO), 8.88 (1H, s, -NH), 8.31 (1H, d, J = 9.0 Hz, -ArH), 3.61-3.58 (2H, m, -
NHCH2CH2CH2N), 2.56 (2H, t, J = 5.4 Hz, -NHCH2CH2CH2N), 2.31 (6H, s, -N(CH3)2), 1.81-
1.77 (2H, m, -NHCH2CH2CH2N). 13C NMR (150 MHz, CDCl3) δ 183.6 (CHO), 165.6 (d, J = 
240 Hz, C2), 159.3 (d, J = 15 Hz, C6), 147.1 (C4), 108.2 (d, J = 30 Hz, C3), 73.2 (C5), 59.4 
(-NHCH2CH2CH2N), 45.4 (-N(CH3)2), 44.1 (-NHCH2CH2CH2N), 24.2 (-NHCH2CH2CH2N). 
ES-MS [M+1] found 352.0, calculated for C11H16FIN3O 352.2. Note: The regioselectivity of 
7d was characterized by the coupling constant (J) in 13C NMR.  
N7-(3-(Dimethylamino)propyl)-6-iodopyrido[2,3-d]pyrimidine-2,7-diamine (7e)199. In 
a 5-mL microwave vessel, a solution of 7d (105 mg, 0.3 mmol) in anhydrous acetonitrile (3 
mL) was treated with guanidine nitrate (44mg, 0.36 mmol) and triethyl amine (101 µL, 0.72 
mmol). The mixture was irradiated with stirring at 150 °C for 60 min (absorption: normal). 
The reaction was subsequently transferred into a 100-mL round bottom flask and dried in 
vacuo.  Silica column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 
7e (37 mg, yield 33%) as a brown oil. TLC (develop twice in 89/10/1 CH2Cl2/MeOH/NH4OH, 
Rf = 0.09). 1H NMR (600 MHz, CDCl3) δ 8.50 (1H, s, -ArH4), 8.13 (1H, s, -NH), 8.08 (1H, s, 
-ArH5), 5.29 (2H, s, -NH2), 3.75 (2H, q, J = 5.6 Hz, -NHCH2CH2CH2N), 2.59 (2H, t, J = 6.0 
Hz, -NHCH2CH2CH2N), 2.35 (6H, s, -N(CH3)2), 1.87-1.83 (2H, m, -NHCH2CH2CH2N). 13C 
NMR (150 MHz, CDCl3) δ 163.1 (C7), 160.9 (C2), 159.4 (C8a), 158.9 (C4), 145.3 (C5), 
110.8 (C4a), 77.9 (C6), 58.9 (-NHCH2CH2CH2N), 45.4 (-N(CH3)2), 43.1 (-NHCH2CH2CH2N), 
24.6 (-NHCH2CH2CH2N). ES-MS [M+1] found 373.0, calculated for C12H18IN6 373.0. 
General method for Suzuki coupling (51-57)199-200. A mixture of 7e (1 eq), boronic acid 
(1.1 eq), Pd(PPh3)4 (0.1 eq) and Na2CO3 (2 eq) was purged with argon three times. A 
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mixture of solvents (1/0.5/0.1 CH3CN/DMF/H2O) was degassed by bubbling with argon for 
10 min and the solvents were added to the solids. The reaction was heated to 90 °C for 5 
h. The resulting solids were moved by filtration, and the filtrate was dried in vacuo. Column 
chromatography over silica gel using the methods below gave the desired compounds, 51-
55. 
6-(2,6-Dimethoxyphenyl)-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7-
diamine (51). Column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 
51 (yield 70%) as a yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.45). 1H NMR 
(600 MHz, CDCl3) δ 8.51 (1H, s, -ArH4), 7.36-7.34 (2H, m, -ArH5, -Ph4’), 6.87 (1H, s, -NH), 
6.65 (2H, d, J = 8.4 Hz, -Ph3’, 5’), 5.36 (2H, s, -NH2), 3.71-3.68 (8H, m, -NHCH2CH2CH2N, 
2×-OCH3), 2.30 (2H, t, J = 6.0 Hz, -NHCH2CH2CH2N), 1.89 (6H, s, -N(CH3)2), 1.68-1.64 (2H, 
m, -NHCH2CH2CH2N). 13C NMR (150 MHz, CDCl3) δ 162.9 (C2), 161.6 (C7), 160.8 (C8a), 
159.2 (C2’, C6’), 158.6 (C4), 140.0 (C5), 130.0 (C4’), 116.4 (C6), 113.0 (C4a), 109.2 (C1’), 
104.1 (C3’, C5’), 59.0 (-NHCH2CH2CH2N), 55.8 (-OCH3), 44.9 (-N(CH3)2), 41.9 (-
NHCH2CH2CH2N), 25.2 (-NHCH2CH2CH2N). ES-MS [M+1] found 382.3, calculated for 
C20H27N6O2 382.2. 
6-(3,5-Dimethoxyphenyl)-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7-
diamine (52). Column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 
52 (yield 66%) as a yellow solid. TLC (develop twice in 89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 
0.47). 1H NMR (600 MHz, CDCl3) δ 8.56 (1H, s, -ArH4), 7.53 (1H, t, J = 4.2 Hz, -NH), 7.41 
(1H, s, -ArH5), 6.51 (3H, s, -Ph2’, 4’, 6’), 5.37 (2H, s, -NH2), 3.82 (6H, s, 2×-OCH3), 3.73-
3.70 (2H, m, -NHCH2CH2CH2N), 2.34 (2H, t, J = 5.4 Hz, -NHCH2CH2CH2N), 1.92 (6H, s, -
N(CH3)2), 1.71-1.67 (2H, p, J = 12 Hz, -NHCH2CH2CH2N). 13C NMR (150 MHz, CDCl3) δ 
163.1 (C2), 161.4 (C7), 161.1 (C3’, C5’), 160.1 (C8a), 159.5 (C4), 138.8 (C1’), 134.3 (C5), 
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123.7 (C6), 108.8 (C4a), 107.2 (C2’, C6’), 100.0 (C4’), 59.2 (-NHCH2CH2CH2N), 55.4 (-
OCH3), 44.9 (-N(CH3)2), 42.5 (-NHCH2CH2CH2N), 24.9 (-NHCH2CH2CH2N). ES-MS [M+1] 
found 382.2, calculated for C20H27N6O2 382.2. 
N7-(3-(Dimethylamino)propyl)-6-(1H-indol-6-yl)pyrido[2,3-d]pyrimidine-2,7-diamine 
(53). Column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 53 (yield 
71%) as a pale yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.18). 1H NMR (600 
MHz, CDCl3) δ 11.23 (1H, s, -InNH), 8.62 (1H,  s, -ArH4), 7.65 (1H, d, J = 8.0 Hz, -InH4’), 
7.55 (1H, s, -ArH5), 7.42 (1H, t, J = 2.8 Hz, -InH2’), 7.40 (1H, s, -InH7’), 7.27 (1H, t, J = 5.2 
Hz, -InH3’), 6.99 (1H, dt, J = 8.1, 1.1 Hz, -InH5’), 6.60 (2H, s, -NH2), 6.49 (1H, t, J = 2.5 Hz, 
-NH), 3.46 (2H, q, J = 6.1 Hz, -NHCH2CH2CH2N), 2.24 (2H, s, -NHCH2CH2CH2N), 1.82 (6H, 
s, -N(CH3)2), 1.63 (2H, p, J = 6.4 Hz, -NHCH2CH2CH2N). 13C NMR (150 MHz, CD3OD) δ 
162.8 (C2), 161.1 (C7), 160.7 (C8a), 159.3 (C4), 136.5 (C6’), 134.7 (C5), 128.8 (C7’a), 
128.1 (C3’a), 125.4 (C2’), 125.3 (C6), 120.6 (C4’), 119.7 (C5’), 111.5 (C7’), 108.6 (C4a), 
101.0 (C4’), 57.4 (-NHCH2CH2CH2N), 43.6 (-N(CH3)2), 40.2 (-NHCH2CH2CH2N), 25.4 (-
NHCH2CH2CH2N). ES-MS [M+1] found 362.3, calculated for C20H24N7 362.2. 
N7-(3-(Dimethylamino)propyl)-6-(1H-indol-5-yl)pyrido[2,3-d]pyrimidine-2,7-diamine 
(54). Column chromatography (97/3/0 to 94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 
54 (yield 69%) as a yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.41). 1H NMR 
(600 MHz, CDCl3) δ 9.17 (1H, s, -InNH), 8.55 (1H,  s, -ArH4), 7.63 (1H, s, -InH4’), 7.48 (1H, 
d, J = 8.3 Hz, -InH6’), 7.43 (1H, s, -ArH5), 7.31 (1H, s, -InH7’), 7.24 (1H, t, J = 2.7 Hz, -NH), 
7.13 (1H, d, J = 8.2 Hz, -InH2’), 6.57 (1H, t, J = 2.4 Hz, -InH3’), 5.34 (2H, s, -NH2), 3.7 (2H, 
q, J = 5.7 Hz, -NHCH2CH2CH2N), 2.28 (2H, t, J = 6.1 Hz, -NHCH2CH2CH2N), 1.78 (6H, s, -
N(CH3)2), 1.67 (2H, p, J = 6.2 Hz, -NHCH2CH2CH2N). 13C NMR (150 MHz, CDCl3) δ 162.8 
(C2), 161.3 (C8a), 161.0 (C7), 159.3 (C4), 135.6 (C5’), 134.5 (C5), 128.3 (C7’a), 127.8 
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(C3’a), 125.4 (C2’), 125.3 (C6), 123.0 (C4’), 121.3 (C6’), 111.7 (C7’), 109.3 (C4a), 102.6 
(C3’), 58.8 (-NHCH2CH2CH2N), 44.8 (-N(CH3)2), 42.0 (-NHCH2CH2CH2N), 25.3 (-
NHCH2CH2CH2N). ES-MS [M+1] found 362.2, calculated for C20H24N7 362.2. 
6-(Cyclohex-1-en-1-yl)-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7-
diamine (55). Column chromatography (99/1/0 to 97/3/0 to 94.5/5/0.5 to 89/10/1 
CH2Cl2/MeOH/NH4OH) gave 55 (yield 71%) as a brown solid. TLC (89/10/1 
CH2Cl2/MeOH/NH4OH, Rf = 0.35). 1H NMR (600 MHz, CDCl3) δ 8.51 (1H,  s, -ArH4), 7.28 
(1H, s, -ArH5), 6.89 (1H, t, J = 5.1 Hz, -NH), 5.83 (1H, dq, J = 3.8, 1.8 Hz, -cyhxH2’), 5.17 
(2H, s, -NH2), 3.73 (2H, q, J = 5.7 Hz, -NHCH2CH2CH2N), 2.46 (2H, t, J = 6.1 Hz, -
NHCH2CH2CH2N), 2.27 (6H, s, -N(CH3)2), 2.24-2.16 (4H, m, cyhxH), 1.84-1.73 (4H, m, 
cyhxH), 1.76-1.67 (2H, m, -NHCH2CH2CH2N). 13C NMR (150 MHz, CDCl3) δ 162.8 (C2), 
160.9 (C8a), 160.0 (C7), 159.2 (C4), 134.1 (C1’), 132.7 (C5), 128.9 (C2’), 126.1 (C6), 109.0 
(C4a), 59.1 (-NHCH2CH2CH2N), 45.6 (-N(CH3)2), 41.7 (-NHCH2CH2CH2N), 29.3 (C6’), 25.6 
(-NHCH2CH2CH2N), 25.4 (C3’), 22.9 (C5’), 21.8 (C4’). ES-MS [M+1] found 327.2, calculated 
for C18H27N6 327.2. 
 
Scheme 19. Synthesis of 56. Reagents and conditions: (a) BBr3, CH2Cl2, 0 ºC, 2 h, 9%. 
5-(2-Amino-7-((3-(dimethylamino)propyl)amino)pyrido[2,3-d]pyrimidin-6-
yl)benzene-1,3-diol (56). The synthesis of compound 56 followed the same procedure as 
for compound 14. A cation exchange column was used for purification. The phosphate 
cellulose resin (Whatman P11 cation exchange) was prepared by soaking the resin in water 
for 30 min before packing. A solution of 1 mL sat. NH4Cl in 25 mL water was used to charge 
the resin followed by flushing with water to remove the excess salt. The material was 
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dissolved in water to load onto the column. The column was eluted by ammonia gradient 
(0-0.8%) and monitored by TLC (78/20/2 CH2Cl2/MeOH/NH4OH, Rf = 0.42). The fractions 
containing the desired product was pooled and lyophilized to give 56 as a white solid (yield 
9%).  1H NMR (600 MHz, CD3OD) 9.42 (1H, s, -ArH4), 8.58 (1H, s, -ArH5), 6.58 (2H, d, J = 
2.1 Hz, -PhH2’, 6’), 6.24 (1H, t, J = 2.1 Hz, -PhH4’), 3.49 (2H, q, J = 6.1 Hz, -
NHCH2CH2CH2N), 2.38 (2H, s, -NHCH2CH2CH2N), 1.98 (6H, s, -N(CH3)2), 1.63 (2H, p, J = 
6.4 Hz, -NHCH2CH2CH2N). 13C NMR (150 MHz, CD3OD) δ 162.4 (C2), 160.0 (C7), 159.4 
(C3’), 156.5 (C8a), 148.1 (C4), 139.9 (C1’), 137.2 (C5), 118.7 (C6), 110.8 (C4a), 107.2 (C2’), 
103.5 (C4’), 47.2 (-N(CH3)2), 43.0 (-NHCH2CH2CH2N), 42.0 (-NHCH2CH2CH2N), 26.3 (-
NHCH2CH2CH2N). ES-MS [M+1] found 355.2, calculated for C18H23N6O2 355.2. 
 
Scheme 20. Synthesis of 57. Reagents and conditions: (a) 10% Pd/C, H2, 40 psi, r.t., 2 h, 
46%. 
6-Cyclohexyl-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7-diamine 
(57)200. A solution of 55 (26 mg, 0.08 mmol) in MeOH (10 mL) was degassed and purged 
with argon three times. To the solution, 10% Pd on activated carbon (6 mg) was added. The 
argon was evacuated and exchanged with H2 gas three times and the reaction was shaken 
under H2 at 40 psi for 2 h. The mixture was filtered through Celite and the filtrate was dried 
in vacuo. Column chromatography (99/1/0 to 97/3/0 to 94.5/5/0.5 CH2Cl2/MeOH/NH4OH) 
gave 57 (12 mg, yield 46%) as a brown solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 
0.35). 1H NMR (600 MHz, CDCl3) δ 8.53 (1H, s, -ArH4), 7.84 (1H, s, -NH), 7.38 (1H, s, -
ArH5), 5.10 (2H, s, -NH2), 3.78 (2H, q, J = 5.4 Hz, -NHCH2CH2CH2N), 2.55 (2H, t, J = 5.4 
Hz, -NHCH2CH2CH2N), 2.37-2.29 (7H, m, -N(CH3)2, cyhxH1’), 1.97-1.87 (4H, m, cyhxH), 
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1.87-1.77 (3H, m, cyhxH), 1.44-1.25 (5H, m, -NHCH2CH2CH2N, cyhxH). 13C NMR (150 MHz, 
CDCl3) δ 162.6 (C2), 160.4 (C6), 160.4 (C7a), 159.0 (C3), 130.2 (C4), 127.4 (C5), 109.2 
(C3a), 60.1 (-NHCH2CH2CH2N), 45.6 (-N(CH3)2), 43.3 (-NHCH2CH2CH2N), 37.6 (C1’), 32.8 
(C2’), 27.1 (C3’), 26.2 (-NHCH2CH2CH2N), 24.5 (C4’). ES-MS [M+1] found 329.2, calculated 
for C18H29N6 329.2. 
General method for the synthesis of 1,8-napthyridines (67-70). 2-Ethoxyethanol 
was dried over K2CO3, distilled and stored over molecular sieves.  To a solution of sodium 
2-ethoxyethoxide (2 eq), prepared from NaH and 2-ethoxyethanol, was added various 
acetonitriles (2 eq). The mixture was stirred under argon at room temperature for 30 min to 
3 h. To the reaction, 9a (1 eq) was added and the reaction was heated at reflux for 3 to 7 h. 
The reaction was cooled to room temperature, poured into cold water and chilled at 4 °C 
overnight. The emulsion was transferred into a separation funnel and extracted by EtOAc 3 
times. The organic layer was combined and washed with brine and then dried over MgSO4. 
After concentration to dryness in vacuo the residue was purified by column chromatography 
using the conditions listed below.  
3-Phenyl-1,8-naphthyridine-2,7-diamine (67). Column chromatography (97/3/0 to 
89/10/1 CH2Cl2/MeOH/NH4OH) gave 67 (yield 74%) as a yellow solid. TLC (94/5/1 
CH2Cl2/MeOH/NH4OH, Rf = 0.22). 1H NMR (600 MHz, DMSO-d6) δ 7.68 (2H, d, J = 8.4 Hz, 
-ArH4), 7.58 (1H, s, -ArH5), 7.48-7.47 (4H, m, -Ph2’, 3’), 7.40-7.37 (1H, m, -Ph4’), 6.45-6.43 
(3H, m, -ArH3, -NH2), 5.97 (2H, s, -NH2). 13C NMR (150 MHz, DMSO-d6) δ 161.0 (C2), 157.8 
(C7), 146.6 (C8a), 138.4 (C1’), 137.6 (C5), 137.6 (C4), 129.4 (C3’, C5’), 129.1 (C2’, C6’), 
127.8 (C4’), 119.3 (C6), 114.9 (C4a), 107.8 (C3). ES-MS [M+1] found 237.1, calculated for 
C14H13N4 237.1. 
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3-(2,6-Dichlorophenyl)-1,8-naphthyridine-2,7-diamine (68). Column 
chromatography (97/3/0 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 68 (yield 19%) as a yellow 
solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.45). 1H NMR (600 MHz, DMSO-d6) δ 7.65 
(1H, d, J = 9.0 Hz, -ArH4), 7.56 (2H, d, J = 8.4 Hz, -Ph3’, 5’), 7.47 (1H, s, -ArH5), 7.43 (1H, 
t, J = 8.4 Hz), 6.51 (2H, s, -NH2), 6.42 (1H, d, J = 8.4 Hz, -ArH3), 5.92 (2H, s, -NH2). 13C 
NMR (150 MHz, DMSO-d6) δ 161.0 (C2), 157.5 (C5), 157.0 (C8a), 138.2 (C4), 137.8 (C7), 
135.8 (C2’, C6’), 135.3 (C1’), 131.0 (C4’), 129.0 (C3’, C5’), 114.7 (C6), 110.0 (C4a), 107.6 
(C3). ES-MS [M+1] found 305.0, calculated for C14H13N4 305.0. 
3-(3,5-Dimethylphenyl)-1,8-naphthyridine-2,7-diamine (69). Column 
chromatography (97/3/0 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 69 (yield 79%) as a yellow 
solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.5 2). 1H NMR (600 MHz, DMSO-d6) δ 
7.64 (2H, d, J = 8.4 Hz, -ArH4), 7.51 (1H, s, -ArH5), 7.04 (2H, s, -Ph2’, 6’), 6.98 (1H, s, -
Ph4’), 6.40 (1H, d, J = 8.4 Hz, -ArH3), 6.35 (2H, s, -NH2), 5.87 (2H, s, -NH2), 2.30 (6H, s, -
CH3). 13C NMR (150 MHz, DMSO-d6) δ 161.0 (C2), 157.8 (C7), 156.2 (C8a), 138.3 (C3’, 
C5’), 138.2 (C1’), 137.5 (C5), 137.2 (C4), 129.2 (C4’), 126.8 (C2’, C6’), 119.4 (C6), 110.9 
(C4a), 107.7 (C3). ES-MS [M+1] found 265.1, calculated for C16H16N4 265.1. 
3-(3,5-Dimethoxyphenyl)-1,8-naphthyridine-2,7-diamine (70). Column 
chromatography (97/3/0 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 70 (yield 97%) as a yellow 
solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.25). 1H NMR (600 MHz, DMSO-d6) δ 7.67 
(2H, d, J = 8.4 Hz, -ArH4), 7.61 (1H, s, -ArH5), 6.60 (2H, d, J = 1.8 Hz, -Ph2’, 6’), 6.51 (1H, 
t, J = 2.1 Hz, -Ph4’), 6.44-6.43 (3H, m, -ArH3, -NH2), 6.05 (2H, s, -NH2), 3.79 (6H, s, -OCH3). 
13C NMR (150 MHz, DMSO-d6) δ 162.1 (C3’, C5’), 161.0 (C2), 157.7 (C7), 156.6 (C8a), 
140.3 (C1’), 137.6 (C5), 137.4 (C4), 119.2 (C6), 110.7 (C4a), 107.8 (C3), 107.0 (C2’, C6’), 
100.0 (C4’), 55.7 (OCH3). ES-MS [M+1] found 297.1, calculated for C14H13N4 297.1. 
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5.2 Biology 
B-PER (Pierce Biotechnologies) were purchased from Fisher. Ampicillin sodium salt, 
Isopropyl β-D-1 thiogalactopyranoside (IPTG) and HisPur Cobalt resin were purchased 
from Gold Biotechnology. ATP was purchased from Sigma-Aldrich. PEP, NADH were 
purchased from Acros. AIR and CAIR were synthesized using literature methods73-74, 104. 
PurK from A. clavatus was purified and stored according to the published methods139-140. 
PurK from E. coli was purified by Jordan Rantucci and stored at -80 ºC. All proteins were 
determined to be >95% pure based on SDS-PAGE analysis. Buffers were stored at 4 ºC 
and stock solutions were stored at -20 ºC. Recombinant cells were purchased from Fisher 
and stored at -80 ºC. During assays, reagents and enzyme were stored on crushed ice.  
UV assays were carried in 1 mL quartz cuvettes on a 1-Bio Cary-3 UV-vis 
spectrophotometer equipped with a temperature controller (Varian) or in flat-bottom 96 well 
plates using a Synergy2 plate reader (BioTek). Thermal shift assays were conducted on a 
Mx3005P qPCR System. Curve fitting was conducted using GraphPad Prism.  
5.2.1 Phosphate Assay (Malachite green assay) 
Reactions were conducted in a flat-bottom 96-well plate (USA Scientific 655101).  Buffer 
(190 µL) was added to each well of the plate (100 mM HEPES, pH 7.8 buffer containing 20 
mM KCl and 6.0 mM MgCl2) followed by the addition of 100 µM AIR, 100 µM ATP, 1 mM 
NaHCO3 and 0.01% (v/v) triton.  Compound stocks in DMSO (10 µL, 5% v/v) were added 
to the sample wells. For single concentration testing, the compound concentration was 200 
µM unless restricted by solubility. Each compound was dispensed into six wells using a 
single channel pipette. To three wells, PurK (𝐴𝑠𝑎𝑚) was added (see below for details) and 
to the remaining three wells, the same volume of buffer was added with these wells serving 
as UV background for that particular compound (𝐶𝑠𝑎𝑚). For dose-response testing, a series 
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of concentrations selected around the estimated IC50 were used, and each concentration 
was tested in triplicate. For kinetic assays, additional variables included ATP concentrations. 
Each plate contained three wells of positive controls (5% DMSO + PurK) (𝐴𝐷𝑀𝑆𝑂) and three 
wells of negative controls (5% DMSO) (𝐶𝐷𝑀𝑆𝑂). Compound 1 served as internal quality 
controls for plates tested on different days. In the reaction wells, 168 ng PurK in 4 µL of 
buffer was added. The UV background and negative control wells were supplemented with 
4 µL of buffer. The reactions were incubated at room temperature for 15 minutes and were 
quenched by the addition of 50 μL of the malachite green reagent (Bioassay Systems) to 
each well.  The plates were incubated at room temperature for an additional 30 minutes and 
the absorbance (620 nm) of each well was measured using a Synergy2 plate reader by 
BioTek. The quality of the plate was verified by the percent residual activity (RA%) of 
compound 1 (43 ± 5%). The plates that passed the quality check were used to calculate the 
RA% of other compounds based on Equation 2. For plates in which the RA% of compound 
1 met the quality cut but was not 43%, RA% of all the compounds were further normalized 
so that RA% of compound 1 was 43%.  
𝑅𝐴% =  
𝐴𝑠𝑎𝑚 − 𝐶𝑠𝑎𝑚
𝐴𝐷𝑀𝑆𝑂 − 𝐶𝐷𝑀𝑆𝑂
 × 100% 
Eq. 2 
5.2.2 PK/LDH coupled PurK assay 
Reactions were conducted in a 1 mL quartz cuvette at 37 ºC.  A master mix containing 
the following components (100 mM HEPES, pH 7.5, 20 mM KCl, 6 mM MgCl2, AIR 25 µM, 
100 µM ATP, NADH 200 µM, PEP 2 mM, triton 0.01% (v/v), 1 mM NaHCO3, 5 units of 
pyruvate kinase/lactate dehydrogenase) was made to ensure consistency. The assay was 
run as follows. Master mix (950 µL) was added to the cuvette followed by the addition of 
compound stock in DMSO; the final DMSO concentration is 5% (v/v). For single 
concentration testing, the compound concentration was 200 µM unless restricted by 
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solubility or high UV absorbance. For dose-response testing, a series of concentrations 
selected around the estimated IC50 were used, and each concentration was tested in triplet. 
For kinetic assays, additional variables included ATP concentrations. The reaction was 
initiated by the addition of 70 ng PurK. NADH oxidation was monitored at 340 nm and the 
initial velocity of each assay was determined from the slope of the change in absorbance 
during the first three minutes. 
5.2.3 Thermal shift assay 
Reactions were conducted in a 200 µM PCR tubes with clear lids. The total volume of 
each reaction is 20 µL. MES buffer (20 mM, pH 6.0) was added followed by the addition of 
0.01 % (v/v) triton, 5x SYPRO Orange and 2 µM PurKAsp (mw 45 kDa calculated as a 
monomer). A series of concentrations of the compound to be tested (stocks in DMSO) were 
added and the final DMSO concentration was kept at 5% (v/v).  Thermal melting curve was 
collected using a RT-PCR instrument (Mx3005P qPCR System) from 25-95 ºC (ramp rate: 
1 ºC/minute) while monitoring the fluorescence of SYPRO Orange (ex = 492 nm, em = 610 
nm). The melting temperature (Tm) was calculated from the maximum of the first derivate 
curve. The dissociation constant Kd was calculated in GraphPad Prism based on a single 
binding model following Equation 3.  
𝒀 = 𝑻𝒎𝒎𝒊𝒏 + (𝑻𝒎𝒎𝒂𝒙 − 𝑻𝒎𝒎𝒊𝒏) × (𝟏
− (𝑷 − 𝑲𝒅 − 𝑿 + √
(𝑷 + 𝑿 + 𝑲𝒅)
𝟐 − (𝟒 × 𝑷 × 𝑿)
𝟐 × 𝑷
)) 
Eq. 2 
𝑻𝒎𝒎𝒂𝒙 : Melting temperature at infinite inhibitor concentration. 𝑻𝒎𝒎𝒊𝒏 : Melting 
temperature at no inhibitor concentration. 𝑃: Protein concentration (2 µM). 𝑋: Inhibitor 
concentration in log unit. 
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5.2.4 Construction, expression and purification of PurK mutant proteins. 
The PurKAsp-pET28 plasmid with an N-terminal His tag of the following sequence 
(MGSSHHHHHHSSENLYFQGH) was used to generate the desired mutant proteins. The 
plasmids for the mutant proteins were generated following the protocol of the Quikchange 
II site-directed mutagenesis kit (Agilent Technologies) using the primers listed in Table 11. 
The nucleotide sequence of each mutant protein was verified by Sanger sequencing at the 
Applied Genomics Technology Center, Wayne State University. The plasmids obtained 
from the mutagenesis was transformed into E. coli BL21(DE3) pLysS recombinant cells for 
protein expression and purification. The expression and purification of the proteins were 
following established methods for PurKAsp139, 142. The purified N-His proteins were used 
directly without cleavage of the His tag. 
Table 11. Primers used for the creation of mutant PurKAsp. 
Mutant Primers 
C266A 5’ cagcatca tgctggccga gatcgccagc 3’ 
 5’ gctggcgatc tcggccagca tgatgctg 3’ 
C266S 5’ cagcatca tgctgagcga gatcgccagc 3’ 
 5’ gctggcgatc tcctcagca tgatgctg 3’ 
C216S 5’ ggaggact cgatatccaa gctcgtgtacgcg 3’     
 5’ cgcgtacacgagc ttggatatcg agtcctcc 3’   
5.2.5 PK/LDH coupled PurK assay used in the study of cysteines functions 
The reactions were run similar as described in section 5.2.2 with N-methyl maleimide 
used as the inhibitor. For continuous assay, the reactions were initiated with the protein 
addition. For reactions where PurK was pre-incubated with N-methyl maleimide, the 
PurK/N-methyl maleimide mixture was used to initiate the reaction.  
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The spread of drug-resistant bacterial infections has increased the need for novel 
antimicrobial agents. One potential but unexplored target is the de novo purine biosynthetic 
pathway. PurK, found only in bacteria, yeast, and fungi, catalyzes the sixth step in purine 
biosynthesis and has no human homolog. Herein we disclose the discovery of the first PurK 
inhibitor with submicromolar potency.  
PurK is a member of the ATP-grasp superfamily of enzymes and recently, nanomolar 
inhibitors of biotin carboxylase, a related enzyme, were published. We hypothesized that 
those inhibitors, which target the ATP-binding site, could also inhibit PurK. To explore this 
hypothesis, four compounds were synthesized and tested against PurK from A. clavatus. 
Only one compound, 1 containing a pyridopyrimidine core, weakly inhibits PurKAsp with an 
IC50 of 167 μM. Kinetic assays have confirmed that 1 is an ATP-competitive inhibitor. With 
the guidance of computational modeling, further optimizations have been focused on the 
ribose and phosphate positions within the ATP-binding site. Both positions gave 
compounds with improved activities. A double-modified compound, 56, merging the best 
compound from each position, inhibits PurKAsp with an IC50 of 1.7 µM, a 100-fold 
improvement in potency. The binding affinity was validated by thermal shift assays. 56 is 
the most potent ATP-binding site inhibitor against PurKAsp described to date.   
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